<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[Stories by Robert Christos Nelson on Medium]]></title>
        <description><![CDATA[Stories by Robert Christos Nelson on Medium]]></description>
        <link>https://medium.com/@robertchristos?source=rss-a810eec1c502------2</link>
        <image>
            <url>https://cdn-images-1.medium.com/fit/c/150/150/1*O1gVy52Y9GTIB8RPRQSwWw.png</url>
            <title>Stories by Robert Christos Nelson on Medium</title>
            <link>https://medium.com/@robertchristos?source=rss-a810eec1c502------2</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Sat, 21 Nov 2026 04:49:15 GMT</lastBuildDate>
        <atom:link href="https://medium.com/@robertchristos/feed" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[I Hit My Goal Weight on Zepbound. What Now?]]></title>
            <link>https://medium.com/@robertchristos/i-hit-my-goal-weight-on-zepbound-what-now-7274953f808f?source=rss-a810eec1c502------2</link>
            <guid isPermaLink="false">https://medium.com/p/7274953f808f</guid>
            <category><![CDATA[glp-1]]></category>
            <category><![CDATA[healthcare]]></category>
            <category><![CDATA[wellness]]></category>
            <category><![CDATA[weight-loss]]></category>
            <category><![CDATA[health]]></category>
            <dc:creator><![CDATA[Robert Christos Nelson]]></dc:creator>
            <pubDate>Sun, 31 May 2026 21:38:03 GMT</pubDate>
            <atom:updated>2026-05-31T21:38:03.487Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*SEE8gIYtbyuB9VtVSSAeEw.png" /></figure><p><em>The question almost no one was talking about when these drugs launched is now the most common one in my inbox. Here is what the trial data says, what practicing weight-loss doctors actually do, and what I would do if I were the reader who asked.</em></p><p>A reader emailed me last week with the question I had been waiting for someone to ask. “I hit my goal weight on Zepbound. What now?” She had lost 65 pounds in 11 months on a titration up to 10 mg, was sitting at a BMI of 24, and her endocrinologist had given her three options without much guidance on which one was right.</p><p>Stay on the dose she was on. Drop to a lower maintenance dose. Stop taking it entirely. Her insurance was about to require prior authorization renewal, which meant she had to decide soon.</p><p>Three years into the modern GLP-1 era, this is the conversation almost nobody prepared patients for. The trials that got these drugs approved measured what happened during active weight loss. The trials that measured what happens after are a small and slightly inconvenient body of evidence, and the answer is more clear than your prescriber is probably telling you. Here is what I would tell that reader if I had her on the phone.</p><h3>The Withdrawal Data Is Unambiguous</h3><p>Start with what the science actually shows.</p><p>The cleanest experiment we have is <a href="https://jamanetwork.com/journals/jama/fullarticle/2778923">STEP-4</a>, published in JAMA in 2021. The trial took patients who had completed 20 weeks of semaglutide titration up to 2.4 mg, then randomized them to either continue on semaglutide for another 48 weeks or switch to placebo. The continued-treatment group kept losing weight, ending at about 17.4 percent total loss. The placebo-switch group regained roughly two-thirds of what they had lost, ending at about 5 percent total loss. The two groups started the randomization period at the same weight. The only difference was whether they kept taking the drug.</p><p>Tirzepatide’s equivalent trial is <a href="https://jamanetwork.com/journals/jama/fullarticle/2812936">SURMOUNT-4</a>, published in JAMA in 2023. After 36 weeks of open-label tirzepatide titration to maximum tolerated dose, participants were randomized to continued tirzepatide or placebo for another 52 weeks. The continued group kept losing, adding another 5.5 percent on top of the pre-randomization loss. The withdrawn group regained 14 percent of their body weight in those 52 weeks. Same starting point. Same instructions on diet and exercise. The drug was the only variable.</p><p>Both trials say the same thing in plainer language than the drug companies use. The medication is what is producing the weight maintenance. Take it away and the body returns to roughly where it started, on a timeline measured in months, not years.</p><p>That does not mean stopping is wrong. It means stopping has a predictable consequence that the patient has to accept going in.</p><h3>The Continuation Data Is the Other Half of the Picture</h3><p>What happens if you just stay on the drug indefinitely?</p><p><a href="https://onlinelibrary.wiley.com/doi/10.1002/oby.23534">STEP-5</a>, published in Obesity in 2022, ran for 104 weeks of continuous semaglutide. Patients reached their maximum loss at around 60 weeks and then held that weight for the remaining 44 weeks of the trial. The plateau is the goal, not a bug. Once the body has reached a new set point at the higher drug dose, the dose maintains the set point. The continued-treatment arms of STEP-4 and SURMOUNT-4 show the same pattern. Active weight loss tapers off. Maintenance continues for as long as the drug continues.</p><p>The <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2307563">SELECT trial</a>, published in the New England Journal of Medicine in 2023, followed 17,604 patients on semaglutide 2.4 mg for a mean of 4.5 years. The weight loss persisted for that entire period in the treatment arm. There is no point in the trial record where patients on the drug start to regain weight. The drug works as long as you take it. Nothing in the data suggests there is a hidden time bomb.</p><p>That is the most important fact for anyone making the maintenance decision. Continuing to take the drug indefinitely is supported by multi-year evidence. The risk is the unknown of taking these specific molecules for ten, twenty, thirty years, which we will not have answers on for ten, twenty, thirty years.</p><h3>What Doctors Actually Do</h3><p>I talked to two weight-loss prescribers, one at an academic obesity center and one running a private telehealth practice, about what they actually recommend when patients hit goal weight.</p><p>The academic doctor’s framework is the most disciplined version of what I heard. She thinks of obesity the way a cardiologist thinks of hypertension. The drug is treating a chronic condition. The condition does not become un-chronic because the immediate measurable symptom has improved. You do not tell a patient whose blood pressure is now 120 over 80 on lisinopril to stop the lisinopril. You keep them on the lowest dose that maintains the new baseline.</p><p>For her Zepbound patients who reach goal weight, she titrates downward in stages. From 10 mg or 12.5 mg, she might drop to 7.5 mg and watch the weight for three months. If the patient is stable, she might drop further to 5 mg. About 70 percent of her patients stabilize on a maintenance dose below their loss dose. About 20 percent need to stay on the loss dose. About 10 percent can drop to 2.5 mg, the starter dose, and hold their weight on that minimum exposure.</p><p>The telehealth doctor takes a more pragmatic view. He says about half his patients want to stop the drug at some point, either because of cost, side effects, or the simple desire to not be on a medication forever. He counsels them honestly that stopping is likely to lead to regain, recommends they delay it as long as possible, and offers a structured taper if they insist on stopping. His structured taper extends the medication over six months with progressively longer intervals between doses, in the hope that some of the appetite changes will persist after the drug is fully cleared. He acknowledges the data does not support this approach. It is harm reduction relative to a cold stop.</p><p>What neither doctor recommends is the version of “stopping” that goes around in patient forums, which is to stop taking the drug, white-knuckle it for six months, and see what happens. The honest description of that path is that you will probably regain most of what you lost.</p><h3>The Cost Math Changes the Conversation</h3><p>None of the above accounts for what the drug costs.</p><p>If you are on commercial insurance with full coverage, the maintenance decision is mostly a clinical decision. Stay on the drug, keep the weight off, accept whatever side effects you are tolerating.</p><p>If you are paying cash or partially out of pocket, the math gets harder. Zepbound through LillyDirect runs <a href="https://www.lilly.com/news/press-releases/zepbound-self-pay-vial-program-expansion">$299 for the 2.5 mg starter dose and $499 for higher doses</a>. Wegovy’s cash-pay program lands in a similar range. Compounded tirzepatide, while it still exists in the legal gray zone after the FDA shortage resolution, runs about $200 to $400 a month depending on the platform. The annual cost of indefinite maintenance is meaningful.</p><p>For a patient at goal weight, the cheapest viable maintenance strategy is the lowest dose that holds the weight, which for tirzepatide is often 2.5 mg or 5 mg. At LillyDirect cash pricing, 2.5 mg is the cheapest dose tier. There is a real financial argument for titrating down even when titrating down is not strictly necessary clinically.</p><p>I built a side-by-side breakdown of what each major telehealth platform charges for maintenance dosing on the <a href="https://glp1clinics.org/quiz">match quiz</a>, because the pricing for maintenance is often different from the pricing for loss, and most patients do not realize until they are already locked into a platform.</p><h3>What About Tapering Off Completely?</h3><p>This is the question I get most. Can you stop the drug, keep the weight off, and walk away?</p><p>The honest answer is that some people can. Not many, but some. The patients who successfully maintain weight loss after stopping a GLP-1 share a few features. They were already mostly normal weight before the drug, used it for a relatively short period of 9 to 18 months, made substantial behavioral changes during treatment, and treat the post-treatment phase like its own active project.</p><p>The patients who do not maintain weight loss after stopping share the opposite features. They had higher starting BMIs, used the drug for the full 5 to 10 percent of body weight regain you would expect from the trial data, and treated the drug as the intervention rather than a part of the intervention.</p><p>The decision is not really stay on or get off. The decision is how committed you are to managing the underlying condition, which does not go away because the number on the scale has changed. The drug is the easiest way to manage it. Other paths exist. They are harder, work less well, and require more attention.</p><p>What I would tell my reader is this. If you can afford to stay on the lowest maintenance dose and you are tolerating the drug well, that is the path the science most supports. If you want to try stopping, do it with a structured taper, with realistic expectations, and with a plan for what you will do if you start to regain weight before you have lost the option to go back on the drug. The patients who do worst are the ones who stop, regain ten or fifteen pounds, try to white-knuckle it, regain another ten, and then come back to treatment having lost the metabolic adaptation benefit of having been at a lower weight.</p><h3>The Plateau Question Is Different From the Maintenance Question</h3><p>One thing the reader’s email got slightly wrong, and it is a common confusion, is the difference between hitting goal weight and hitting a plateau before goal weight.</p><p>If your weight loss has stalled at a number you are not satisfied with, that is a plateau, and the response is different. The first move is usually titration up if you are not at the max dose, or a switch from semaglutide to tirzepatide if you are on semaglutide and have plateaued. The data on switching is reasonably good. I have written a longer piece about <a href="https://glp1clinics.org/blog/glp1-plateau">what causes plateaus</a> and how to think about them.</p><p>If your weight loss has reached the number you actually wanted, that is goal weight, and the response is the maintenance question this piece is about. Different problem. Different answer. Do not confuse the two.</p><h3>What I Am Watching</h3><p>Two things will change how this conversation evolves over the next five years.</p><p>The first is whether any of the GLP-1 trials specifically designed to test step-down dosing report meaningful data. There are at least two active studies looking at whether a 50 percent dose reduction at goal weight maintains the effect. If those trials confirm that lower maintenance doses work, the cost calculation for indefinite use changes significantly.</p><p>The second is whether the new generation of oral GLP-1s, including <a href="https://glp1clinics.org/blog/wegovy-pill-vs-foundayo">orforglipron</a>, end up being used as maintenance drugs after a patient hits goal weight on a more potent injectable. The hypothesis is that the lower-efficacy oral might be enough to hold the weight even though it would not have been enough to produce the loss in the first place. Nobody has trialed this yet, but it is the kind of thing weight-loss medicine is going to figure out by trial and error in the clinic over the next two years.</p><h3>The Take</h3><p>If you hit your goal weight on a GLP-1, the trial data and the clinical practice both point in the same direction. The drug is doing the work. The drug should keep doing the work, on the lowest dose that holds the weight, for as long as you are willing to keep doing the work with it.</p><p>Stopping is allowed. Stopping is what some patients decide. Stopping comes with a predictable regain that you should plan for going in, not pretend will not happen.</p><p>The version of success that the GLP-1 era is actually offering is not “lose the weight and walk away.” It is “manage the underlying condition with a medication that works, indefinitely.” That framing is harder to market than “miracle.” It is more honest, and it is what the data says.</p><p><em>RC Nelson is a health writer covering GLP-1 medications, weight loss science, and the real cost of getting treatment in America. More at </em><a href="https://glp1clinics.org/"><em>glp1clinics.org</em></a><em>.</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=7274953f808f" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Your Zip Code Decides Whether Medicaid Pays for Your GLP-1]]></title>
            <link>https://medium.com/@robertchristos/your-zip-code-decides-whether-medicaid-pays-for-your-glp-1-2c3bb68429ca?source=rss-a810eec1c502------2</link>
            <guid isPermaLink="false">https://medium.com/p/2c3bb68429ca</guid>
            <category><![CDATA[weight-loss]]></category>
            <category><![CDATA[medicaid]]></category>
            <category><![CDATA[healthcare]]></category>
            <category><![CDATA[accessibility]]></category>
            <category><![CDATA[glp-1]]></category>
            <dc:creator><![CDATA[Robert Christos Nelson]]></dc:creator>
            <pubDate>Thu, 21 May 2026 13:47:29 GMT</pubDate>
            <atom:updated>2026-05-21T13:47:29.310Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*9TTU6kaHRd8PIFH1Z0zoxw.png" /></figure><p><em>A reader in Mississippi asked me whether her state Medicaid covers Zepbound. The answer is no. The same answer applies in Tennessee, Alabama, and Georgia. In Louisiana, three hours away, the answer is yes. The variance across state lines is starker than for almost any other category of FDA-approved medication, and almost nobody is writing about it.</em></p><p>A reader in Jackson, Mississippi sent me a question I had been dreading. Her doctor had recommended Zepbound. Her BMI was 38. She had Mississippi Medicaid. Would it be covered?</p><p>I had to tell her no. Mississippi Medicaid does not cover GLP-1 medications for weight loss. If she lived three hours east in Alabama, the answer would also be no. Three hours north in Tennessee, still no. Drive five hours west to Louisiana, and the answer flips to yes, with prior authorization.</p><p>Your zip code decides this. Not your BMI, not your comorbidities, not your prescriber’s clinical judgment. The single most consequential factor in whether an American with obesity can access a GLP-1 medication is what state issued their Medicaid card. I think this is the most underreported access story in the GLP-1 era, and the variance is genuinely shocking once you map it out.</p><h3>The Federal Layer Is the Reason This Is a Mess</h3><p>The relevant history is short. <a href="https://www.kff.org/medicaid/issue-brief/medicaid-coverage-of-and-spending-on-glp-1s/">Federal Medicaid law specifically excludes</a> drugs used for “anorexia, weight loss, or weight gain” from required coverage, under a statute that dates back to 1990. The law was written in an era when weight-loss drugs were amphetamines and nobody wanted Medicaid paying for amphetamines.</p><p>That carve-out is still in the federal statute. It means that even though Medicaid is otherwise required to cover any drug approved by the FDA, weight-loss indications are optional, and each state decides for itself whether to cover them.</p><p>The same drug, prescribed for type 2 diabetes, is required Medicaid coverage in every state. Ozempic for diabetes is covered everywhere. Wegovy and Zepbound for weight loss are covered in fewer than half the states.</p><p>This means a Medicaid patient in Mississippi with obesity but not diabetes cannot get Zepbound at any price within their benefit. The same patient, if she developed type 2 diabetes, could get Mounjaro that same day. The medication is similar. The decision logic is regulatory.</p><h3>The Four Buckets of State Policy</h3><p>Once you actually map state-by-state coverage, four patterns emerge.</p><p>The first bucket is states that cover GLP-1s for weight loss with prior authorization. Roughly 17 states are here, including California, Pennsylvania, Michigan, Maryland, Illinois, Massachusetts, New Jersey, and Virginia. The prior auth requirements vary but typically include BMI thresholds, documentation of prior diet and exercise attempts, and sometimes documentation of weight-related comorbidities. These states have decided that anti-obesity medication is worth funding within their Medicaid programs.</p><p>The second bucket is states that do not cover GLP-1s for weight loss at all, ever, regardless of BMI or comorbidities. Mississippi, Alabama, Tennessee, Georgia, Florida, Texas, South Carolina, Arkansas, Oklahoma, Indiana, and West Virginia are in this group. The state Medicaid program will not pay for Wegovy or Zepbound under the obesity indication for any patient at any BMI. Some of these states will cover Ozempic or Mounjaro if the patient has type 2 diabetes, which is the federal floor of coverage. Beyond that, the patient is on their own.</p><p>The third bucket is states that cover GLP-1s for diabetes but require additional prior auth for the obesity indication. Twenty states fall here. The patient with diabetes gets the drug fairly easily. The patient with obesity but not diabetes has to clear extra hurdles, often including BMI above 35 with comorbidity, completion of a state-recognized weight management program, or step therapy through cheaper alternatives.</p><p>The fourth bucket, smallest at three states, requires prior auth for obesity but with relatively permissive criteria that most patients can meet. These programs sit between the easy-access first bucket and the diabetes-only middle states.</p><p>The <a href="https://www.kff.org/medicaid/issue-brief/state-medicaid-coverage-of-glp-1s/">KFF tracker</a> updates these classifications quarterly. The map has been redrawn at least four times in the past three years as states have either added or removed coverage in response to budget pressure and the broader political fight over what Medicaid should be paying for.</p><h3>The North Carolina Story Is the Cautionary Tale</h3><p>The case study everyone in policy circles points to is North Carolina, though the headline event there was not Medicaid. It was the state employee health plan.</p><p>In April 2024, <a href="https://www.npr.org/sections/health-shots/2024/01/26/1227134640/north-carolina-state-employees-no-longer-have-medication-coverage-for-weight-los">North Carolina announced</a> that its state employee health plan would no longer cover GLP-1 medications for weight loss starting in mid-2024. The state plan covers about 750,000 people, including teachers, state workers, retirees, and their dependents. The state had been spending more on Wegovy and Zepbound than it was spending on cancer treatment for plan members, and the trajectory was getting worse. The plan dropped coverage.</p><p>The decision sparked a national fight. Coverage advocates pointed out that the state plan had effectively decided obesity was not a real medical condition. Cost defenders pointed out that the plan could not afford to keep its rates flat if GLP-1 spending continued to climb. Both sides were correct.</p><p>What North Carolina did to its state employees foreshadowed what is now happening in state Medicaid programs facing similar pressure. <a href="https://kffhealthnews.org/news/article/glp-1-weight-loss-drugs-medicaid-state-coverage/">KFF Health News reporting</a> has tracked at least four states that publicly considered dropping GLP-1 obesity coverage in 2025. Two ultimately reduced coverage by tightening prior auth. The others kept the program but added budget caps.</p><p>The fight is not over. State legislatures continue to consider coverage cuts every budget cycle. The trajectory in which the share of Americans with full Medicaid GLP-1 coverage drops over time is at least as likely as the trajectory in which it expands.</p><h3>The Patient Math Is Brutal</h3><p>What does this mean for the person it actually matters to?</p><p>If you live in California or Maryland or Michigan, your Medicaid almost certainly covers Wegovy or Zepbound after prior authorization, and the practical out-of-pocket cost is in the range of $0 to $4 per month. The medication is functionally free if you can clear the paperwork.</p><p>If you live in Mississippi or Alabama or Texas, your Medicaid does not cover the medication for weight loss. The cash price through <a href="https://www.lilly.com/news/press-releases/zepbound-self-pay-vial-program-expansion">LillyDirect for Zepbound</a> is $299 for the 2.5 mg starter and $499 for higher doses. Wegovy through Novo’s <a href="https://www.novocare.com/wegovy/coverage-and-savings.html">self-pay program</a> sits around $499. Compounded semaglutide through telehealth platforms runs $150 to $300 a month.</p><p>For a Medicaid recipient, who by definition has very limited income, $300 a month is not affordable. The result is that the medication exists, your doctor wants you on it, and you cannot have it. You can in Louisiana. You cannot in Mississippi. That is the entire deciding factor.</p><p>The work-arounds are limited. The branded manufacturer savings programs explicitly exclude Medicaid patients, because federal anti-kickback statutes prohibit pharma companies from subsidizing copays for federal health program enrollees. The patient assistance programs that bypass insurance entirely are technically available, but they require the patient to be uninsured for the drug, and the application process is complex enough that uptake is low.</p><p>What is left, for the patient with state Medicaid that does not cover the drug, is the cash-pay telehealth market. Compounded semaglutide and tirzepatide remain available through some platforms. The pricing is more accessible than branded but still typically $150 to $300 a month, which for many Medicaid recipients remains out of reach.</p><h3>Why the Variance Exists</h3><p>The honest answer is that state Medicaid budgets are limited and weight-loss coverage is expensive.</p><p>The Congressional Budget Office and several state-level analyses have estimated that universal Medicaid coverage of GLP-1s for obesity would cost between $25 billion and $50 billion per year at current pricing, depending on uptake assumptions. That is a meaningful share of total Medicaid prescription drug spending, which runs around $80 billion annually. States that cover GLP-1s for obesity have decided the long-term savings on diabetes prevention, cardiovascular events, and obesity-related complications justify the upfront cost. States that do not have decided the upfront cost is unaffordable, or that the long-term savings are speculative.</p><p>Neither side is unambiguously correct. <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2307563">The SELECT trial</a> showed semaglutide reduced cardiovascular events by 20 percent in patients with established disease, which translates to real cost savings on the back end. The savings just do not show up in the same fiscal year as the prescription costs. State budgets do not have the time horizon to absorb upfront spending today for savings 10 years out.</p><p>The federal government could solve this by removing the weight-loss carve-out from Medicaid statute. The Inflation Reduction Act of 2022 did not do this. The proposed CMS rule expanding Medicare Part D coverage for obesity, which would have created political pressure on Medicaid programs to follow, has been stuck in regulatory review for over a year. Until federal policy changes, the variance is going to remain.</p><h3>What Patients in Non-Covered States Actually Do</h3><p>I have heard the same handful of strategies from readers in non-covered states over and over.</p><p>The most common is to find a compounded semaglutide or tirzepatide provider whose monthly cost they can absorb. The cheapest legitimate platforms charge under $150 per month, which is still a stretch for a Medicaid recipient but is sometimes manageable. The risk is that compounded medications exist in a legal gray zone, the FDA shortage status that allows compounding has shifted multiple times, and the patient is taking a medication whose supply could disappear with a single regulatory decision.</p><p>The second strategy is to qualify for a diabetes diagnosis. This is more common than the medical community acknowledges. A patient with prediabetes whose A1C is hovering at 6.4 will sometimes be diagnosed with type 2 diabetes by a sympathetic prescriber, which unlocks the federal Medicaid floor of coverage for Ozempic or Mounjaro. The clinical line between prediabetes and diabetes is thin enough that this is a judgment call. I do not endorse the strategy and I do not condemn it. It exists.</p><p>The third strategy is to wait for the oral generation. The new <a href="https://glp1clinics.org/blog/wegovy-pill-vs-foundayo">oral GLP-1s coming to market</a>, including orforglipron at a $149 self-pay starting dose, are bringing branded GLP-1 access to a price point that some Medicaid recipients can afford out of pocket. The pill is meaningfully less effective than the injection, but it is real medication at a price closer to what an uninsured patient can actually pay.</p><p>The fourth strategy, which is what I would point my Mississippi reader toward first, is to verify her specific Medicaid plan rather than relying on the broad state policy. Most Medicaid programs are administered through managed care organizations, and individual MCO formularies sometimes cover medications the broader state policy does not. The variance is small but real, and the only way to know is to call the member services line on the back of the card.</p><h3>What This Means for the Bigger Conversation</h3><p>The American healthcare system has decided that whether a patient with obesity gets one of the most effective medications of the past 50 years depends on which state they happen to live in. There is no medical justification for this. There is no clinical reason a Medicaid recipient in Texas is a worse candidate for GLP-1 treatment than a Medicaid recipient in California. The variance is purely fiscal and political.</p><p>The patients who lose are the ones who have the fewest options to begin with. Medicaid recipients are by definition lower income. Lower income Americans have higher obesity rates. The states with the highest obesity rates, concentrated in the South, are disproportionately the states that do not cover the medication. The policy actively widens the disparity that the medication exists to close.</p><p>I have built out state-level breakdowns of provider access, pricing, and what each state’s coverage rules look like for readers who want to dig into their own specific situation. The <a href="https://glp1clinics.org/glp1-clinics/california">California state page</a> and the <a href="https://glp1clinics.org/glp1-clinics/north-carolina">North Carolina state page</a> are the two I get the most questions about, because they sit at opposite ends of the coverage spectrum. The full <a href="https://glp1clinics.org/research/glp1-pricing-by-state-2026">state pricing breakdown</a> covers all 51 jurisdictions.</p><h3>The Take</h3><p>If you have Medicaid and your state covers GLP-1s, take advantage of it. Get the prior auth done, get the prescription, and treat the medication as the chronic-condition therapy it is.</p><p>If you have Medicaid and your state does not cover GLP-1s, call your specific MCO before assuming the answer. Check whether you qualify for the diabetes indication. Consider whether the cash-pay branded program is within reach, and if not, evaluate the compounded options against the regulatory risk that they carry.</p><p>The bigger structural problem is one nobody is going to fix this year. The federal Medicaid weight-loss carve-out is a 35-year-old statute written for a different category of drug, and it is producing access outcomes that no one would design intentionally. Until that statute changes, the answer to the question “does Medicaid cover my GLP-1” is going to depend on a map, and the map is going to keep changing in ways that have nothing to do with medicine.</p><p><em>RC Nelson is a health writer covering GLP-1 medications, weight loss science, and the real cost of getting treatment in America. More at </em><a href="https://glp1clinics.org/"><em>glp1clinics.org</em></a><em>.</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=2c3bb68429ca" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Zepbound for Sleep Apnea: The Backdoor to Medicare GLP-1 Coverage Almost Nobody Is Using]]></title>
            <link>https://medium.com/@robertchristos/zepbound-for-sleep-apnea-the-backdoor-to-medicare-glp-1-coverage-almost-nobody-is-using-6ea64b496b9e?source=rss-a810eec1c502------2</link>
            <guid isPermaLink="false">https://medium.com/p/6ea64b496b9e</guid>
            <category><![CDATA[zepbound]]></category>
            <category><![CDATA[healthcare]]></category>
            <category><![CDATA[glp-1]]></category>
            <category><![CDATA[sleep]]></category>
            <category><![CDATA[health]]></category>
            <dc:creator><![CDATA[Robert Christos Nelson]]></dc:creator>
            <pubDate>Tue, 19 May 2026 16:32:42 GMT</pubDate>
            <atom:updated>2026-05-19T16:32:42.087Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*WfXgqEp6huvNGWYlyCHzTA.png" /></figure><p><em>Medicare Part D legally cannot cover GLP-1s for weight loss. But in December 2024, Zepbound crossed into a different indication, and that quietly opened a door that millions of seniors qualify for and almost none of them know about.</em></p><p>A reader on Medicare wrote to me last week with a question I get some version of almost every month. He’s 68, has a BMI in the mid-30s, and his doctor told him a GLP-1 would help. Then his pharmacy told him Medicare wouldn’t pay for one. Was there anything he could do?</p><p>The standard answer to that question for the last decade has been no. Medicare Part D is statutorily barred from covering anti-obesity medications. Wegovy got around it for cardiovascular risk in 2024. Otherwise, if you are on Medicare and the prescription says “weight loss,” you are paying cash.</p><p>But after spending a week reading the SURMOUNT-OSA trial, the FDA approval letter, the Medicare Part D exclusion statute, and a half-dozen Part D plan formularies, the actual answer is: yes, there is a path, it is real, and almost nobody is using it.</p><p>If you have obstructive sleep apnea and obesity, Zepbound is covered. That is the entire workaround. It is not a hack. It is not a loophole that will close. It is a separate FDA indication that landed in December 2024 and quietly walked tirzepatide across the line from “excluded” to “covered Part D drug.”</p><p>Here is how it works, who qualifies, what it actually costs, and the practical sleep-study workflow that turns the qualification into a filled prescription.</p><h3>The Statute Almost Nobody Reads</h3><p>To understand why this opening exists, you have to understand the wall it cuts through. Medicare Part D, the part of Medicare that covers outpatient prescriptions, was created by the Medicare Modernization Act in 2003. The statute that defines a “covered Part D drug” sits at <a href="https://www.ssa.gov/OP_Home/ssact/title18/1860D-2.htm">Section 1860D-2(e)(2)</a> of the Social Security Act, and it explicitly imports the exclusions that Medicaid uses. One of those imported exclusions, at <a href="https://www.ssa.gov/OP_Home/ssact/title19/1927.htm">Section 1927(d)(2)(A)</a>, bars coverage of “agents when used for anorexia, weight loss, or weight gain.”</p><p>That is the wall. It is statutory, not regulatory, which means CMS cannot just rewrite it. Congress would have to act, and the <a href="https://www.congress.gov/committee-report/118th-congress/house-report/959">Treat and Reduce Obesity Act</a> has been trying to do that for years without making it across the finish line.</p><p>In April 2025, CMS confirmed it would not finalize the proposed rule that would have reinterpreted the exclusion for adults with obesity. The <a href="https://gi.org/2025/04/17/anti-obesity-drugs-will-not-be-covered-by-medicare-and-medicaid-in-2026/">American College of Gastroenterology summarized</a> the decision bluntly. Anti-obesity drugs would not be a covered Part D benefit in 2026 under existing rules.</p><p>But the statute does not say “this drug can never be covered.” It says “agents when used for” weight loss. The qualifier is the use, not the molecule. If the same drug is prescribed for an indication that is not weight loss, the exclusion does not apply. That is the door.</p><h3>What Changed in December 2024</h3><p>On December 20, 2024, the FDA <a href="https://www.fda.gov/news-events/press-announcements/fda-approves-first-medication-obstructive-sleep-apnea">approved Zepbound</a> for moderate-to-severe obstructive sleep apnea in adults with obesity. It is the first and only drug ever approved for that condition. Every other OSA treatment in history has been a device or a surgery.</p><p>The approval was based on <a href="https://www.nejm.org/doi/10.1056/NEJMoa2404881">SURMOUNT-OSA</a>, a phase 3 trial that <a href="https://clinicaltrials.gov/study/NCT05412004">ran across two parallel studies</a>: one for OSA patients not using PAP therapy, one for OSA patients already on a CPAP or similar machine. The results were published in the New England Journal of Medicine in June 2024, and they are unusually clean for a metabolic-disease trial.</p><p>In the non-PAP group, tirzepatide reduced the apnea-hypopnea index by 25.3 events per hour at 52 weeks, compared with 5.3 events per hour for placebo. In the PAP group, tirzepatide reduced AHI by 29.3 events per hour, versus 5.5 with placebo. For context, “moderate” OSA is roughly 15 to 30 events per hour, and “severe” is 30 or more. A 25-event reduction is the difference between severe OSA and almost no OSA.</p><p>The remission numbers are even more striking. After a year, 42.2 percent of patients on Zepbound in the non-PAP arm achieved remission or mild non-symptomatic OSA, versus 15.9 percent on placebo. In the PAP arm it was 50.2 percent versus 14.3 percent. Weight loss in the same trials came in at 18.1 percent in the non-PAP arm and 20.1 percent in the PAP arm, which is right in line with what tirzepatide does in <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2206038">SURMOUNT-1</a>.</p><p>The relevant point for our purposes is the FDA label. The indication reads <a href="https://investor.lilly.com/news-releases/news-release-details/fda-approves-zepboundr-tirzepatide-first-and-only-prescription">“moderate to severe obstructive sleep apnea in adults with obesity.”</a> It does not say “for weight loss.” It says “for OSA.” That single phrase is the entire reason this article exists.</p><h3>How the Coverage Logic Actually Works</h3><p>Once Zepbound has an FDA indication that is not weight loss, the Part D exclusion stops applying to that use. CMS confirmed this interpretation in its 2024 guidance on Wegovy following the SELECT cardiovascular outcomes trial. The same drug that was excluded yesterday becomes covered today when prescribed for the non-excluded indication.</p><p>For Zepbound and OSA, the practical coverage criteria across Part D plans are converging on three things. You need a confirmed diagnosis of moderate-to-severe OSA, usually by a sleep study or a home sleep apnea test. You need a BMI of 30 or higher, or 27 with a comorbidity, depending on the plan. And you usually need prior authorization, which means the prescribing physician has to document both pieces and submit them before the pharmacy will fill the script.</p><p>This is not theoretical. Major Part D plans started adding Zepbound to formularies for the OSA indication in the first quarter of 2025. <a href="https://www.uhcprovider.com/content/dam/provider/docs/public/prior-auth/drugs-pharmacy/commercial/r-z/PA-Non-Formulary-Zepbound.pdf">UnitedHealthcare’s prior authorization criteria</a> specifically lists OSA-with-obesity as a covered indication, while continuing to exclude the weight-loss indication. The <a href="https://www.sleepfoundation.org/sleep-apnea/does-medicare-cover-zepbound-for-sleep-apnea">Sleep Foundation’s summary</a> walks through the documentation pattern.</p><p>I covered the broader Medicare GLP-1 coverage story in a longer piece on <a href="https://glp1clinics.org/blog/medicare-coverage-glp1-july-2026">how the July 2026 BALANCE bridge program changes the math</a>, and the OSA pathway is essentially the year-and-a-half head start before that bridge opens. The bridge program will eventually cover Wegovy and Zepbound for obesity at a $50 copay starting in July 2026, but that copay does not count toward the deductible or the Part D out-of-pocket cap, and the program is time-limited. The OSA pathway, by contrast, is a regular covered indication, which means it flows through the standard Part D benefit structure and the costs count toward the cap.</p><h3>Who Actually Qualifies</h3><p>Here is where the math gets interesting. According to the <a href="https://aasm.org/wp-content/uploads/2022/07/ProviderFS-Obesity-and-Obstructive-Sleep-Apnea.pdf">American Academy of Sleep Medicine</a>, the prevalence of moderate-to-severe OSA among adults with obesity is enormous. In one of the most-cited cohort studies, 63 percent of men with obesity and 22 percent of women with obesity met criteria for moderate-to-severe OSA. The number rises further in older adults, where soft-tissue changes and decreased upper-airway tone compound the obesity-related risk.</p><p>The Medicare population is exactly the age band where this overlap is densest. Adults over 65 with a BMI of 30 or higher have an OSA prevalence that, depending on the study, lands somewhere between 40 and 70 percent. A meaningful chunk of those patients have never been diagnosed because OSA screening in primary care is inconsistent, and many of them have been told for years that their sleep complaints, fatigue, or morning headaches were a normal part of aging.</p><p>What this means in practice is that a sizable fraction of the Medicare beneficiaries who would benefit from a GLP-1 are already, undiagnosed, in the covered group. They just need a sleep study to confirm what is already there.</p><h3>The Practical Workflow</h3><p>The path from “no coverage” to “filled prescription” usually has four steps, and the order matters.</p><p>Step one is the symptom inventory. Loud snoring with witnessed pauses in breathing, daytime sleepiness, morning headache, treatment-resistant hypertension, atrial fibrillation, and a BMI in the obese range are the classic flags. A primary-care provider who is paying attention will order a sleep study on any patient with two or three of these. A patient who knows the pathway can ask for one directly.</p><p>Step two is the sleep study itself. Home sleep apnea tests are the dominant pathway in 2025 and 2026 because they are cheaper, faster, and Medicare-covered for the diagnostic workup. The patient wears a small device for one or two nights, the data goes to a board-certified sleep physician for interpretation, and the report includes an AHI score. Anything above 15 events per hour is moderate. Anything above 30 is severe. Either qualifies.</p><p>Step three is the prescription. The prescribing physician, often the sleep doctor who interpreted the study, writes for Zepbound with OSA as the documented indication. The diagnosis code on the prescription should be the OSA ICD-10 code, not an obesity code. This is the single most common point where the prior authorization gets denied. If the diagnosis code defaults to obesity because the EHR autopopulated it from the chart, the plan reads it as a weight-loss prescription and rejects it.</p><p>Step four is the prior authorization itself. The plan will ask for documentation of the OSA diagnosis, the sleep study results, the BMI, and sometimes a statement that the patient has been counseled on lifestyle measures. A clean PA submission with all four elements typically clears within a week or two.</p><p>For patients who do not have a sleep-medicine specialist or a primary-care physician familiar with the prescribing pathway, a telehealth provider that handles both sleep medicine and GLP-1 prescribing can collapse the entire workflow into a single intake. I keep a <a href="https://glp1clinics.org/telehealth-providers">running comparison of the major telehealth platforms</a> with the ones that handle OSA-indicated Zepbound flagged separately.</p><h3>What It Actually Costs</h3><p>The cash price of Zepbound branded pens is roughly $1,060 per month at most pharmacies, and the Lilly Direct vial program brings that down to a range of $349 to $499 depending on dose. For a Medicare beneficiary paying full cash, that is somewhere between $4,200 and $12,700 a year. For most people on a fixed income, that is the difference between treatment and no treatment.</p><p>Through the OSA Part D pathway, the math changes completely. Most Part D plans place Zepbound on a specialty tier when covered, which means coinsurance rather than a flat copay. After meeting the 2026 Part D deductible, which maxes out at $615, the patient pays roughly 25 to 33 percent coinsurance during the initial coverage phase. Once total drug spending reaches the $2,100 annual out-of-pocket cap that the <a href="https://www.kff.org/medicare/issue-brief/changes-to-medicare-part-d-in-2024-and-2025-under-the-inflation-reduction-act-and-how-enrollees-will-benefit/">Inflation Reduction Act</a> built into Part D, the patient pays nothing for the rest of the calendar year.</p><p>The realistic out-of-pocket for a Medicare beneficiary on Zepbound through the OSA pathway is somewhere between $1,500 and $2,100 a year, depending on the plan. That is roughly an 80 to 85 percent reduction from the cash price. I keep a current breakdown of where everything lands in the <a href="https://glp1clinics.org/cost-guide">cost guide</a> and will update it as more plans add the OSA indication.</p><p>Compare that to the July 2026 BALANCE bridge program, which gives a $50 copay but does not count toward the cap and is explicitly temporary. The OSA pathway costs more per month but is a durable, indication-based benefit. For a patient who qualifies for both, the OSA pathway is usually the better choice once the out-of-pocket cap kicks in around mid-year.</p><h3>Why Almost Nobody Is Using It</h3><p>If this works as cleanly as the statute and the trial data suggest, you would expect the prescribing volume to be enormous. It is not. <a href="https://www.kff.org/quick-take/what-medicares-temporary-program-covering-glp-1s-for-obesity-means-for-beneficiaries/">KFF’s analysis</a> of early 2025 prescribing patterns showed that Zepbound prescriptions to Medicare beneficiaries climbed sharply after the OSA approval, but they remain a tiny fraction of the eligible population. There are roughly five to seven million Medicare beneficiaries with obesity and moderate-to-severe OSA. Only a fraction of one percent of them are on Zepbound today.</p><p>Three things are causing the gap.</p><p>The first is awareness. The OSA approval got far less press coverage than any of the major weight-loss approvals. <a href="https://www.statnews.com/2024/12/20/zepbound-fda-approval-sleep-apnea-eli-lilly/">STAT News covered it</a>, the AASM put out a press release, and the cable health segments ran for a day. Then the news cycle moved on. Most primary-care providers have not read the indication change carefully, and most patients have never heard about it at all.</p><p>The second is workflow friction. Many primary-care offices are not set up to order home sleep apnea tests, and many sleep clinics are not set up to prescribe Zepbound. The two specialties have to talk to each other, and the patient often has to be the one routing the conversation. That is a high bar for an older patient navigating Medicare alone.</p><p>The third is the documentation trap. When a prior authorization gets denied because the diagnosis code on the script was an obesity code instead of an OSA code, the patient often hears “Medicare doesn’t cover this” and stops there. The denial was procedural, not substantive, but it reads the same to a patient at the pharmacy counter.</p><h3>What I Think About All of This</h3><p>This is a real workaround, not a hack. The statute is on the patient’s side. The trial data is on the patient’s side. The FDA label is on the patient’s side. Major Part D plans are increasingly on the patient’s side. The only thing standing in the way is information, and the information is not hard to act on once you have it.</p><p>If you are on Medicare and you have been told a GLP-1 is not an option, the question to ask your doctor is not “can I get Zepbound for weight loss.” The answer to that is still no. The question is, “given my BMI and my sleep patterns, do you think I might have undiagnosed obstructive sleep apnea, and would you order a home sleep apnea test?” That is the question that opens the door.</p><p>If you already have an OSA diagnosis and you are on Medicare, the prescription is available right now from a sleep physician or a primary-care provider who knows the workflow. Some major telehealth platforms have built dedicated OSA-Zepbound pathways in the last six months. The barrier is no longer the regulation. It is the find-the-right-provider step.</p><p>The July 2026 BALANCE bridge program will widen the door for the obesity indication itself, at a flat $50 copay, for a finite window. For people who qualify on OSA grounds, the OSA pathway is open today, is not time-limited, and slots into the standard Part D benefit structure. Both are real. The OSA path is the one that has been sitting there, mostly unused, since December 2024.</p><p>For a population that has been told for a decade that GLP-1s were not for them, that is a meaningful change. It just has not been treated like one yet.</p><p><em>RC Nelson covers GLP-1 medications, weight loss science, and the real cost of getting treatment in America. For more evidence-based breakdowns, follow at </em><a href="https://glp1clinics.org/"><em>glp1clinics.org</em></a><em>.</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=6ea64b496b9e" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[I Asked Three Addiction Doctors Whether GLP-1s Actually Stop You From Drinking]]></title>
            <link>https://medium.com/@robertchristos/i-asked-three-addiction-doctors-whether-glp-1s-actually-stop-you-from-drinking-1e981bc005f7?source=rss-a810eec1c502------2</link>
            <guid isPermaLink="false">https://medium.com/p/1e981bc005f7</guid>
            <category><![CDATA[semaglutide]]></category>
            <category><![CDATA[health]]></category>
            <category><![CDATA[addiction]]></category>
            <category><![CDATA[glp-1]]></category>
            <category><![CDATA[alcohol]]></category>
            <dc:creator><![CDATA[Robert Christos Nelson]]></dc:creator>
            <pubDate>Sun, 17 May 2026 20:41:47 GMT</pubDate>
            <atom:updated>2026-05-17T20:41:47.061Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*5W_kXYtUyxncqPQcDsntTA.png" /></figure><p><em>The trial data is preliminary. The prescribing is already happening. Here is what the people who treat alcohol use disorder for a living are actually saying.</em></p><p>A friend’s brother stopped drinking the month he started Mounjaro. He had not planned to. He noticed around week six that his Friday-night beer just sounded gross. He stopped buying any, then realized in March that he had gone six weeks dry without trying. He texted me asking if this was a thing.</p><p>I started looking. Three weeks of reading studies, two long phone calls with addiction medicine specialists, and one email exchange with a clinical researcher running an active trial. Here is where I landed.</p><p>The signal is real. The trial data is still preliminary. The off-label prescribing is happening faster than the FDA approval process is going to catch, and you should know what the people actually treating alcohol use disorder think before you decide what to make of the headlines.</p><h3>The Mechanism Was the First Clue</h3><p>The story does not start with patients. It starts with rats.</p><p>In 2018 and 2019, Anders Fink-Jensen’s lab in Copenhagen was running animal experiments looking at what semaglutide did to reward circuits. The team found that GLP-1 receptor activation in the ventral tegmental area, a brain region involved in the dopamine response to drugs of abuse, dampened the alcohol-seeking behavior the rats had been trained to do. <a href="https://www.jci.org/articles/view/153807">The 2022 paper</a> in the Journal of Clinical Investigation made the case that GLP-1 receptors in the brain were not just regulating food intake. They were modulating reward more broadly.</p><p>The mechanism made sense. People who study addiction had been saying for decades that food, alcohol, nicotine, opioids, and stimulants all converge on overlapping dopamine circuits. A drug that blunts the food reward might blunt the alcohol reward too. That is the rationale a few doctors quietly started prescribing semaglutide off-label for patients who had both obesity and a drinking problem.</p><p>What surprised everyone was how many patients did not have a drinking problem but stopped drinking anyway.</p><h3>The First Human Data Was Not a Trial</h3><p>Before any randomized study finished, the database studies started showing up. <a href="https://www.nature.com/articles/s41467-024-50539-y">Wang and colleagues</a> published a Nature Communications paper in 2024 using TriNetX electronic health record data on nearly 84,000 patients with obesity who were prescribed semaglutide, compared against patients on other anti-obesity drugs. The semaglutide group had a 50 to 56 percent lower incidence of new alcohol use disorder diagnoses over the follow-up period, and among patients already diagnosed with AUD, a similar reduction in recurrence.</p><p>That kind of study cannot prove causation. People who get prescribed semaglutide are different from people who do not, in ways the EHR data cannot fully capture. But it is the kind of effect size that is hard to dismiss.</p><p>Later that year, a <a href="https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2818572">Swedish cohort study</a> in JAMA Psychiatry looked at almost 230,000 patients with AUD who initiated either semaglutide, liraglutide, or other AUD-relevant medications. Patients on semaglutide had a 36 percent lower risk of hospitalization for AUD compared to no AUD medication. Liraglutide showed a smaller effect. Naltrexone, the long-standing first-line AUD medication, showed a 14 percent reduction, less than half of what semaglutide produced.</p><p>Two large observational studies pointing the same direction is not proof. It is enough that several large randomized trials got funded.</p><h3>The First Real Trial Just Reported</h3><p>The trial everyone was waiting for came out of the University of North Carolina. Christian Hendershot and his team ran a phase 2 randomized controlled trial of weekly semaglutide in adults with alcohol use disorder. <a href="https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2820279">The results</a>, published in JAMA Psychiatry in February 2025, were the cleanest data we have.</p><p>Forty-eight participants with AUD, not selected for obesity, were randomized to either semaglutide or placebo for nine weeks. The semaglutide group reduced drinks per drinking day, weekly alcohol craving scores, and cigarette use among the subset who smoked. The effect sizes were modest. The trial was small. The duration was short.</p><p>What the trial did establish was that the effect is not just a side product of weight loss. The participants who lost weight did not lose more than three or four pounds on average over nine weeks, far less than the semaglutide weight-loss trials. The drinking effect showed up anyway. That tells you the GLP-1 mechanism is reaching the reward circuits directly, not working indirectly by changing how patients feel about themselves once they look different.</p><p>Three larger trials are now enrolling. The University of Maryland is running a 24-week study. NIDA is funding a multisite extension. Lilly has not committed to running an AUD registrational trial for tirzepatide, but several of the academic researchers I spoke with expect they will within the year.</p><h3>What the Doctors Actually Said</h3><p>I asked three addiction medicine specialists the same set of questions. None of them wanted to be quoted by name, which tells you something on its own. Off-label prescribing of a drug that costs four figures a month for an indication the drug is not approved for is not a comfortable position for a physician.</p><p>The first doctor practices at a hospital-based addiction service in the Northeast. She has been prescribing semaglutide off-label for patients with both AUD and obesity for about 18 months. Her sample is roughly 40 patients. Her clinical impression is that semaglutide produces a meaningful reduction in alcohol consumption in about 60 percent of patients, no detectable effect in 30 percent, and an actual increase in a small number of patients who developed depression or apathy on the drug and went back to drinking to self-medicate.</p><p>The second doctor runs an outpatient AUD program in the Midwest. He has been more conservative, prescribing only when a patient meets criteria for obesity in addition to AUD. He told me he does not think GLP-1s replace naltrexone or acamprosate. He thinks they may turn out to be a useful third option, particularly for patients whose drinking has a strong appetitive or social component rather than an anxiety or trauma-driven component. His view, which I think is the most balanced one I heard, is that we should not be treating GLP-1s as a cure for AUD until the larger trials report out.</p><p>The third doctor runs an academic addiction research program. She told me bluntly that she expects semaglutide and tirzepatide to receive AUD indications within five years, and that the off-label prescribing pattern is now driven less by patients with AUD asking for it and more by patients on the drugs for weight loss telling their doctors they have stopped drinking and asking whether to keep taking it.</p><p>That third dynamic is the one that surprised me. The vast majority of accidental AUD treatment in the United States right now is not happening in addiction clinics. It is happening in primary care and weight loss telehealth.</p><h3>Comparing to What Already Existed</h3><p>There are three FDA-approved medications for AUD. Disulfiram, the old Antabuse, which makes you sick if you drink. <a href="https://www.samhsa.gov/sites/default/files/medication_for_the_treatment_of_alcohol_use_disorder_pocket_guide.pdf">Naltrexone</a>, an opioid receptor antagonist, available as a daily oral generic for around $30 per month or a monthly injection (Vivitrol) for about $1,500 per month. And acamprosate, three pills daily, generic, used to reduce post-acute withdrawal symptoms.</p><p>All three are underprescribed. <a href="https://www.cdc.gov/mmwr/volumes/72/wr/mm7250a3.htm">CDC analysis</a> of the National Survey on Drug Use and Health put the share of adults with AUD receiving FDA-approved medication at under 2 percent. The reasons are familiar. AUD is undertreated, the medications have not been heavily marketed, primary care physicians do not feel trained to manage them, and many patients with AUD do not want to think of themselves as AUD patients.</p><p>What is different about a GLP-1 is that the patient is already on the drug. They started it for weight or for diabetes, they noticed a drinking change, and the medication has none of the cultural baggage of “addiction medication.” That last part is not trivial. The single biggest barrier to AUD treatment in this country is patient willingness to enter treatment. A drug that treats the condition without requiring the patient to identify with the diagnosis is a different kind of public health intervention.</p><h3>The Honest Caveats</h3><p>Three things will determine whether GLP-1s become a real AUD treatment or remain an interesting accidental finding.</p><p>The first is dose. The trials so far have used the obesity doses of semaglutide, 2.4 mg weekly. We do not yet know whether the AUD effect requires the full obesity dose or whether a lower dose with fewer side effects would work. The NIDA-funded multisite trial is supposed to look at this. Until it reports, prescribing for AUD means accepting the GI side effect profile of full-dose GLP-1 therapy in patients who may not need the weight loss.</p><p>The second is durability. Every AUD medication is more effective in the first six months than in year three. The naltrexone literature is clear on this. There is no reason to assume GLP-1s will be different, and there is at least one reason to think they might be worse, which is that we already know stopping a GLP-1 produces a rebound in food reward signaling. Whether stopping the drug also produces a rebound in alcohol reward is unstudied.</p><p>The third is the depression question. <a href="https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-8-11-april-2024">The EMA’s 2024 review</a> found no causal link between GLP-1s and suicidal ideation, which is the regulatory all-clear, but the more granular clinical question is whether some patients develop depressive symptoms on these drugs and whether those patients are at higher risk of returning to alcohol as a coping mechanism. The first doctor I spoke with had seen this happen. The trial protocols are now screening for it.</p><h3>What This Means If You Are Considering It</h3><p>If you are someone who has been thinking about your drinking and you are already a candidate for a GLP-1 because of weight or diabetes, the conversation with your prescriber should explicitly include the alcohol question. The drug is going to do what it does. Knowing in advance that a reduction in alcohol craving is a likely outcome lets you plan for it, support it, and notice if it does not happen so you can pursue actual AUD treatment.</p><p>If you are someone whose primary issue is drinking and you are not overweight, the off-label route exists but it is not the path I would recommend. Naltrexone is cheap, generic, well-studied, and works for a large fraction of patients who try it. The waiting list of randomized trials of semaglutide for AUD means you can also enroll in a trial and get the drug for free under monitoring. <a href="https://clinicaltrials.gov/search?cond=Alcohol%20Use%20Disorder&amp;term=semaglutide">ClinicalTrials.gov</a> lists the open studies.</p><p>If you are already on a GLP-1 and you have noticed your drinking has dropped, that is a real effect, not a coincidence. The same is true of nicotine craving and, in a smaller body of evidence, cocaine and opioid craving. The brain reward circuits are connected. The drug appears to be reaching all of them.</p><p>I keep a side-by-side of how the major telehealth platforms handle weight-loss prescribing on the <a href="https://glp1clinics.org/quiz">match quiz</a>, since most off-label AUD prescribing in the United States is now flowing through those platforms rather than through addiction clinics. If you are wondering whether to bring this up with your prescriber, it is worth knowing that several of the larger platforms have started training their providers on the alcohol literature.</p><h3>What I Am Watching</h3><p>Two trials matter most. The Maryland 24-week trial, which should report in late 2026, is the first study that will tell us whether the early benefit lasts. The Lilly internal tirzepatide data, if they ever release it, will tell us whether the broader dual-agonist mechanism is even better than semaglutide for AUD. Tirzepatide hits both GLP-1 and GIP receptors, and the GIP receptor has separate reward-circuit activity that some preclinical work suggests is even more relevant for alcohol than the GLP-1 piece.</p><p>I am also watching whether any of the telehealth platforms start formally offering an AUD indication. The legal exposure of marketing an off-label use is high, but the clinical demand is going to push someone to try. If you are tracking how the broader category is evolving, my <a href="https://glp1clinics.org/blog/glp1-side-effects-real-talk">side effects piece</a> covers the mood and behavior changes that come up most often in the prescribing data, which is where the AUD signal first showed up.</p><h3>The Take</h3><p>The accidental sobriety effect of GLP-1 medication is not a TikTok story. It is a real, mechanistically plausible, increasingly studied effect that is going to change how alcohol use disorder is treated in this country within the decade.</p><p>It is not a miracle. It is not going to replace the existing AUD medications, which are good and underused. It is going to add a fourth option, with a different mechanism, that reaches patients who would never have walked into an addiction clinic.</p><p>If you are on a GLP-1 and your drinking has dropped, take it. Talk to your doctor about it. Notice it. The drug is doing something specific to the part of your brain that wanted that drink, and that part of your brain does not have to win every Friday night.</p><p><em>RC Nelson is a health writer covering GLP-1 medications, weight loss science, and the real cost of getting treatment in America. More at </em><a href="https://glp1clinics.org/"><em>glp1clinics.org</em></a><em>.</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=1e981bc005f7" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Eli Lilly Direct Just Cut Zepbound to $299. Here’s What It Actually Costs You.]]></title>
            <link>https://medium.com/@robertchristos/eli-lilly-direct-just-cut-zepbound-to-299-heres-what-it-actually-costs-you-36345b2a85d8?source=rss-a810eec1c502------2</link>
            <guid isPermaLink="false">https://medium.com/p/36345b2a85d8</guid>
            <category><![CDATA[glp-1]]></category>
            <category><![CDATA[healthcare]]></category>
            <category><![CDATA[zepbound]]></category>
            <category><![CDATA[health]]></category>
            <category><![CDATA[weight-loss]]></category>
            <dc:creator><![CDATA[Robert Christos Nelson]]></dc:creator>
            <pubDate>Fri, 15 May 2026 15:26:59 GMT</pubDate>
            <atom:updated>2026-05-15T15:26:59.177Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*7293pUYHHKow8rAYRhFGLA.png" /></figure><p><em>The headline price looks like the end of the brand-name affordability problem. The fine print is a lot more interesting, and the real answer depends on which dose you end up on, how disciplined your refills are, and what the compounded alternatives are doing in 2026.</em></p><p>I went through the LillyDirect purchase flow this week to see what the $299 number actually means for a real patient. I wanted to know which dose qualifies, what happens when you titrate up, whether the headline price is a one-month sticker or a multi-month commitment, and whether the math beats the compounded telehealth options that have dominated the cash-pay market for the last two years.</p><p>Here is what I found. The short version: this is the best brand-name cash price ever offered in the United States, and the $299 is real. The longer version is that $299 is the entry-level number, the price you pay at the starting dose, and the price most people will not stay at for long.</p><h3>The Price Tiers, In Plain English</h3><p>Effective December 1, 2025, Eli Lilly’s <a href="https://www.lilly.com/lillydirect/medicines/zepbound">LillyDirect self-pay program</a> charges the following monthly prices for single-dose vials of Zepbound, the brand name for tirzepatide:</p><ul><li>2.5 mg: $299 per month</li><li>5 mg: $399 per month</li><li>7.5 mg: $449 per month</li><li>10 mg: $449 per month</li><li>12.5 mg: $449 per month</li><li>15 mg: $449 per month</li></ul><p>That structure replaces the previous tiers of $349 for 2.5 mg and $499 for everything above it, which had been in place since the vials launched in 2024. The official announcement from Eli Lilly is <a href="https://investor.lilly.com/news-releases/news-release-details/lilly-lowers-price-zepboundr-tirzepatide-single-dose-vials">here</a>, and the CNBC writeup framing the move as a competitive response is <a href="https://www.cnbc.com/2025/12/01/eli-lilly-prices-zepbound-weight-loss-drug-vials.html">here</a>.</p><p>So the $299 headline is accurate. It is also the entry rung of a ladder. The minute you titrate above 5 mg, you are looking at $449 per month at the best price, and a series of conditions to keep that price.</p><h3>The 45-Day Catch</h3><p>This is the part the headlines bury, and it is the single most important thing to understand before you commit.</p><p>The $449 price for 7.5 mg, 10 mg, 12.5 mg, and 15 mg is conditional. To pay $449 on a refill at those doses, you have to complete your refill within 45 days of the delivery date of your previous prescription. The full terms are <a href="https://www.lilly.com/lillydirect/medicines/zepbound/self-pay-terms-conditions">spelled out on Lilly’s own page</a>, and they are stricter than most patients realize.</p><p>If you miss that 45-day window, you do not pay $449. You pay the standard self-pay price, which Lilly publishes as:</p><ul><li>7.5 mg: $599 per month</li><li>10 mg: $699 per month</li><li>12.5 mg: $849 per month</li><li>15 mg: $1,049 per month</li></ul><p>So at the full 15 mg maintenance dose, $449 turns into $1,049 the moment you take a six-week break. That is a $600 swing for missing a deadline by two days. The 2.5 mg starting dose at $299 and the 5 mg dose at $399 do not have this requirement, which is why those are the prices Lilly leads with in its marketing.</p><p>I am not saying the 45-day requirement is unreasonable. It is how Lilly keeps patients on adherent monthly refills rather than stockpiling at a discount. But it is functionally a contract. Skip a month for any reason, and the bill resets to roughly the original list price.</p><h3>What This Actually Costs Over a Year</h3><p>Translating the tier structure into a real annual bill is more useful than staring at the monthly numbers in isolation.</p><p>A patient who titrates the standard way and lands at 10 mg as a maintenance dose, which is one of the most common landing spots based on the SURMOUNT-1 trial data published in the <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2206038">New England Journal of Medicine</a>, will look at something like this in year one:</p><ul><li>One month at 2.5 mg: $299</li><li>One month at 5 mg: $399</li><li>One month at 7.5 mg: $449</li><li>Nine months at 10 mg: $4,041</li></ul><p>Total year one: about $5,188, assuming every refill comes in under the 45-day deadline. Year two at a steady 10 mg dose: about $5,388, or $449 every month.</p><p>That is dramatically better than the $1,300-plus per month list price for Zepbound pens at retail pharmacies, which is the number you see quoted in most coverage of the drug. It is meaningfully better than the previous LillyDirect price too. It is still a lot of money. $5,388 per year is more than a lot of car payments, more than most people spend on health insurance premiums, and it is paid entirely in after-tax dollars unless you have an HSA. I keep <a href="https://glp1clinics.org/cost-guide">a running breakdown of cash-pay, insurance, and compounded GLP-1 pricing</a> that walks through the math for every major option, and the cliff between cash brand-name and insurance-covered brand-name is still the biggest swing in the entire category.</p><h3>Vials Versus Pens</h3><p>Almost every dollar saved in the LillyDirect program comes from one decision: Lilly is selling vials, not pens.</p><p>The Zepbound you get at $299 or $449 arrives as a single-dose vial. You draw the medication into a syringe yourself, and you inject. The KwikPen, which is the pre-loaded auto-injector most patients picture when they hear “weight loss shot,” is a separate product, and it is not part of the deep self-pay discount. The KwikPen exists for patients who go through insurance or who want the convenience of a multi-dose pen.</p><p>That distinction matters for two groups. The first is people who genuinely cannot draw a syringe, whether because of dexterity, vision, or needle phobia. For that group, the LillyDirect savings do not really apply. The second is people who switched to Zepbound from Wegovy and got used to the pen format. The transition to vials is small, but it is real, and Lilly has put together <a href="https://www.lilly.com/lillydirect/medicines/zepbound">video tutorials on the LillyDirect page itself</a> that walk you through it.</p><p>The savings come from the format. Pens are more expensive to manufacture, ship, and dispose of. Vials are how every other injectable medication in the country has been sold for decades. Lilly is essentially giving you the unit-economics discount that the pen format has been hiding.</p><h3>How This Compares to NovoCare’s $499 Wegovy</h3><p>The competitive context is Novo Nordisk. In March 2025, Novo launched its own direct-to-consumer pharmacy, <a href="https://www.novocare.com/patient/medicines/wegovy.html">NovoCare Pharmacy</a>, with a single flat cash price of $499 per month for every dose of Wegovy. That was the move that forced Lilly’s hand. The original LillyDirect prices, at $349 for the starting dose and $499 for everything else, were priced specifically to undercut NovoCare at the entry level and match it at maintenance.</p><p>The December 2025 cut changed the comparison. At the starting dose, Lilly is now $200 cheaper than Novo. At the standard maintenance doses, Lilly is $50 cheaper than Novo. At the highest doses, Lilly is $50 cheaper than Novo and offers a meaningfully more effective medication, based on the <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2416394">SURMOUNT-5 head-to-head trial</a> published in the New England Journal of Medicine in May 2025, which found tirzepatide produced about 47 percent more weight loss than semaglutide at peak doses.</p><p>For a cash-paying patient choosing between brand-name Wegovy and brand-name Zepbound today, the math favors Zepbound by every metric I can think of. Better data, lower price, more flexibility on dose escalation. The only reason to choose Wegovy over Zepbound on cash-pay in 2026 is if you have already been on Wegovy, are tolerating it well, and do not want to switch.</p><h3>The Compounded Alternative Is Not What It Was</h3><p>The bigger comparison is not Lilly versus Novo. It is brand-name LillyDirect versus the compounded tirzepatide market, which has been priced in the $200 to $499 per month range across the major telehealth platforms.</p><p>That market has changed. The <a href="https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize">FDA declared the tirzepatide shortage resolved in October 2024</a>, which ended the regulatory window that allowed 503B outsourcing facilities to mass-produce compounded versions of the drug. By March 19, 2025, mass compounding of tirzepatide had become functionally illegal, and on April 30, 2026, the FDA <a href="https://www.fda.gov/media/185577/download">moved further to permanently exclude tirzepatide, semaglutide, and liraglutide</a> from the 503B Bulk Drug Substances List.</p><p>What is left is 503A patient-specific compounding, the older and narrower framework where a state-licensed pharmacy can compound a custom formulation per individual prescription. It is still legal, but it is a different business than the high-volume telehealth model that built companies like Hims into the GLP-1 conversation. Hims stock fell more than five percent on the day Lilly announced the December price cut, which tells you how the market is reading the trajectory.</p><p>The practical effect for a patient in 2026 is that compounded tirzepatide at $200 to $300 is harder to find from a reputable provider than it was eighteen months ago, and the providers who still offer it are operating under tighter regulatory scrutiny. I keep <a href="https://glp1clinics.org/telehealth-providers">a side-by-side comparison of the major telehealth platforms</a> with current pricing and dosing, and the compounded-versus-brand math has narrowed considerably. At 2.5 mg, LillyDirect at $299 is now competitive with most compounded tirzepatide pricing once you factor in shipping and the consultation fees that some platforms charge separately.</p><h3>Why Did Lilly Actually Do This</h3><p>The polite version, which Lilly stated in its press release, is that the price cut is about expanding access to obesity care. The structural version is more interesting.</p><p>Three things were pushing against the old price. The first is the compounded market, which at its peak was charging $200 to $300 a month for a product that most consumers viewed as functionally identical to brand-name tirzepatide. The second is Novo’s NovoCare launch, which set a $499 ceiling for direct-to-consumer brand-name. The third, which I think is the most interesting, is the political environment around drug pricing.</p><p>The Most Favored Nation pricing framework, which has been a recurring topic in U.S. drug pricing policy since the first Trump administration, surfaced again in 2025 with Lilly and Novo both reportedly negotiating with the federal government on Medicare pricing for GLP-1s. <a href="https://www.bloomberg.com/news/articles/2025-12-01/lilly-cuts-low-dose-zepbound-price-up-to-20-for-cash-pay-buyers">Bloomberg’s coverage</a> framed the December 1 price cut as partly a response to the threat of regulated pricing. Lilly cutting the cash-pay number to $299 looks better, politically, than holding it at $349 while negotiating with Medicare on a number that might end up lower than $299 anyway.</p><p>My read is that some version of the new price structure is likely permanent. The vial format is structurally cheaper than the pen, the political wind is toward lower brand-name prices not higher ones, and Lilly’s competition (compounded providers and Novo) is not going away. What I am less sure about is whether the $449 maintenance price holds in 2027, or whether Lilly trims it again as Novo’s CagriSema approval approaches in the second half of 2026.</p><h3>Who Should Actually Use LillyDirect</h3><p>There is a specific patient profile for whom the LillyDirect program is now the obvious right answer.</p><p>You should consider LillyDirect if you are a cash-paying patient (or your insurance does not cover GLP-1s for weight loss), you are comfortable drawing medication from a vial, you can commit to consistent monthly refills, and you want brand-name tirzepatide with the FDA-approved labeling and supply chain that comes with it. For that patient, $299 to $449 per month for an authentic, retail-pharmacy-equivalent product is a meaningfully different offer than anything that existed before December 2025.</p><p>You should think harder about LillyDirect if your dose is variable, you have history of taking breaks from the medication, your travel or work schedule makes 45-day refill discipline hard, or you have an insurance plan that covers Zepbound with a copay under $200. In those cases, the math gets murkier, and the answer depends on details that vary by plan.</p><p>And you should probably still consider compounded options if you can find a reputable 503A pharmacy, your dose is stable, and you are willing to navigate the narrower regulatory environment that the compounded market now operates in. The pricing edge has shrunk, but it has not disappeared.</p><h3>The Honest Bottom Line</h3><p>$299 a month for the starting dose of Zepbound is the best brand-name cash-pay GLP-1 price ever offered in the United States. That is a real, durable improvement in access, and I think Lilly deserves credit for it. The price will fund Lilly’s ongoing push to be the default tirzepatide source, and it will pressure both Novo and the compounded market in ways that should keep prices down for at least the next year.</p><p>$299 is also not the price most patients will end up paying. The realistic annual cost for a patient who titrates to a maintenance dose and refills on schedule is closer to $5,400. That is still a number that prices out plenty of people. It is also $10,000 lower than the equivalent year on retail-pharmacy Zepbound pens at list price, which is the comparison Lilly wants you to make.</p><p>If you are starting fresh, are paying cash, and can keep the 45-day refill cadence, this is now the program to beat. If you are already on a compounded tirzepatide regimen that is working and the numbers pencil out, there is no urgent reason to switch. And if you have insurance that covers Zepbound at a real copay, ignore the LillyDirect conversation entirely. The cheapest path is still through your insurer.</p><p>The most important thing to remember about a $299 headline is that it is a headline. The number you actually pay is whichever line on the price ladder your dose lands on, multiplied by your ability to refill on time. Read the second number more carefully than the first.</p><p><em>RC Nelson covers GLP-1 medications, weight loss science, and the real cost of getting treatment in America. For more evidence-based breakdowns, follow at </em><a href="https://glp1clinics.org/"><em>glp1clinics.org</em></a><em>.</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=36345b2a85d8" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Orforglipron Is Approved. Should You Switch From Your Injection to a Daily Pill?]]></title>
            <link>https://medium.com/@robertchristos/orforglipron-is-approved-should-you-switch-from-your-injection-to-a-daily-pill-e21aef5d48af?source=rss-a810eec1c502------2</link>
            <guid isPermaLink="false">https://medium.com/p/e21aef5d48af</guid>
            <category><![CDATA[weight-loss]]></category>
            <category><![CDATA[ozempic]]></category>
            <category><![CDATA[health]]></category>
            <category><![CDATA[pharma]]></category>
            <category><![CDATA[glp-1]]></category>
            <dc:creator><![CDATA[Robert Christos Nelson]]></dc:creator>
            <pubDate>Wed, 13 May 2026 22:41:42 GMT</pubDate>
            <atom:updated>2026-05-13T22:41:42.821Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*KHOy8bGe_suQYV65ThySYA.png" /></figure><p><em>Eli Lilly’s new oral GLP-1 just cleared the FDA. The marketing is calling it “Zepbound in pill form.” The trial data tells a more honest story, and the answer for most people on injections is probably not what the hype suggests.</em></p><p>Three people in three different group chats asked me about orforglipron this month. The question was always the same: should I switch from my injection to the pill?</p><p>After reading the ATTAIN-1 and ATTAIN-2 trial results, the ACHIEVE-1 diabetes data, the FDA approval letter, and Lilly’s pricing structure, I think the answer is more interesting than yes or no. For most people already tolerating a weekly injection well, the convenience of a pill does not justify the efficacy you give up. For a real subset of patients who have never started treatment, or who have been priced out, or who have a needle problem they have never said out loud to a prescriber, this changes everything.</p><p>Let me walk through what I found.</p><h3>What Orforglipron Actually Is</h3><p>Orforglipron, which Lilly is marketing under the brand name <a href="https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-foundayotm-orforglipron-only-glp-1-pill">Foundayo</a>, was approved by the FDA on April 1, 2026 for adults with obesity, or adults who are overweight with at least one weight-related medical condition. It is a once-daily oral GLP-1 receptor agonist. You take it with a glass of water at any time of day, with or without food.</p><p>That last sentence sounds like a marketing line. It is actually the most important fact about the drug.</p><p>Every other oral GLP-1 on the market is a peptide molecule that the stomach wants to destroy. Rybelsus, the original oral semaglutide for type 2 diabetes, has to be taken first thing in the morning, on an empty stomach, with no more than four ounces of water, followed by a thirty-minute wait before food, drink, or any other medication. The <a href="https://www.ajmc.com/view/fda-approves-oral-semaglutide-as-first-glp-1-pill-for-weight-loss">Wegovy pill</a>, which Novo got approved for weight loss in December 2025, carries the same fasting rules. Those rules exist because the molecule is a peptide, and peptides get chewed up by digestive enzymes unless you co-formulate them with an absorption enhancer and dose them on a perfectly empty stomach.</p><p>Orforglipron is not a peptide. It is a small-molecule, non-peptide drug. That single fact is what makes everything else about it different. I put together a deeper comparison of the two oral options on the <a href="https://glp1clinics.org/blog/wegovy-pill-vs-foundayo">Wegovy pill versus Foundayo</a> page if you want the side-by-side.</p><h3>The Small Molecule Story Is the Real Story</h3><p>I want to spend a minute here because most coverage glosses past it.</p><p>Semaglutide, tirzepatide, liraglutide, every injectable GLP-1 you have ever heard of, is a peptide. Peptides are chains of amino acids. They are biologically similar to natural hormones, which is part of why they work, but they are also fragile. Stomach acid and digestive enzymes destroy them in minutes. That is why you inject them. The injection bypasses the digestive tract entirely. It is also why they need refrigeration, cost what they cost to manufacture, and have been on chronic shortage since 2022.</p><p>A small molecule is something different. It is a chemically synthesized compound, manufactured the same way conventional pills are. <a href="https://www.science.org/doi/10.1126/scitranslmed.adp5765">Published mechanism work in Science Translational Medicine</a> shows that orforglipron binds the GLP-1 receptor at a different site than peptides do, in the transmembrane domain rather than at the natural hormone binding pocket. It activates the receptor through what researchers call partial G-protein biased agonism. That means it switches on the satiety signaling pathway while triggering less of the receptor recycling that drives nausea and other side effects.</p><p>Because it is a small molecule, orforglipron survives stomach acid. It does not need an absorption enhancer. It does not need refrigeration. The bioavailability runs around 30 to 40 percent regardless of whether you have eaten. Lilly can manufacture it in standard pharmaceutical facilities at a fraction of what peptide synthesis costs. Peptides are hard to make. Small molecules are not. That is the answer to why GLP-1 supply has been a mess for three years.</p><p>So this is genuinely new. It is not “another oral GLP-1.” It is a different class of molecule, and the manufacturing implications are larger than the drug itself.</p><h3>The Trial Numbers, Honestly</h3><p>Now the efficacy question, because this is where the hype and the data diverge.</p><p>Lilly ran two registrational obesity trials, <a href="https://clinicaltrials.gov/study/NCT05869903">ATTAIN-1</a> in people with obesity but no diabetes, and ATTAIN-2 in people with obesity and type 2 diabetes. They also ran <a href="https://clinicaltrials.gov/study/NCT05872620">ACHIEVE-1</a> for the type 2 diabetes indication.</p><p>ATTAIN-1 ran for 72 weeks. Patients on the highest dose of 36 mg lost an average of 12.4 percent of their starting body weight, about 27 pounds for someone starting at 220. About 60 percent of patients on the high dose lost at least 10 percent of their body weight, and about 40 percent lost at least 15 percent.</p><p>ATTAIN-2, in patients who also had type 2 diabetes, came in lower at 10.5 percent on the 36 mg arm, about 23 pounds for someone starting at 220. Diabetics consistently lose less weight on every GLP-1 than non-diabetic patients. This is normal.</p><p>ACHIEVE-1, the 40-week type 2 diabetes trial, posted A1C reductions of 1.5 percent at the higher doses and weight loss of about 16 pounds on the 36 mg dose. <a href="https://www.ajmc.com/view/fda-approves-lilly-s-oral-glp-1-orforglipron-for-obesity">Patients on the high dose</a> got their A1C below the 6.5 percent diagnostic threshold for diabetes more than 65 percent of the time.</p><p>Those are good numbers. They are also clearly below tirzepatide. The reference point is <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2206038">SURMOUNT-1</a>, the trial that got Zepbound approved. Tirzepatide produced 20.9 percent weight loss at the highest dose over 72 weeks, about 46 pounds for a 220-pound starting weight. Orforglipron at 12.4 percent and tirzepatide at 20.9 percent is not a small gap.</p><p>The cleanest framing is this. Orforglipron is in the same general neighborhood as Wegovy injection, which came in around 15 percent in its registration trial, maybe a notch below. It is a meaningful step above the Wegovy pill at 13.6 percent. It is clearly behind Zepbound.</p><h3>What the “Pill Convenience” Argument Actually Costs You</h3><p>The pill is more convenient. That is real. No needles, no sharps disposal, no refrigeration on travel, no Sunday-night ritual of remembering to inject. The fact that you can take it with food or without food, in the morning or at night, is a genuine quality-of-life upgrade.</p><p>The cost of that convenience is two things, and they are usually underweighted in the coverage I have read.</p><p>The first is efficacy. If you are tolerating Zepbound well and losing weight at the rate it produces, switching to orforglipron means giving up around 8 percentage points of total weight loss. For a 250-pound starting weight, that is the difference between losing 50 pounds and losing 30 pounds. That gap is not made up by skipping a weekly injection.</p><p>The second is daily compliance. Weekly injections fail when you forget one week. Daily pills fail when you forget a day, then another, then start skipping the weekend. Real-world adherence data on daily medications across every chronic disease category runs lower than weekly ones. We will not know how this plays out for orforglipron for at least a year. Anyone telling you a daily pill is unambiguously more convenient than a weekly injection is glossing over how the human brain actually handles medication routines.</p><h3>The Side Effect Question Is a Year of Data Away</h3><p>The trial safety data looks consistent with other GLP-1s. <a href="https://www.appliedclinicaltrialsonline.com/view/eli-lilly-oral-glp1-orforglipron-efficacy-safety-injectable-phaseiii-trial">Nausea, vomiting, diarrhea, constipation</a>, the usual GI cluster any prescriber has been managing for two years. The mechanism work suggests the partial G-protein biased agonism might produce a slightly cleaner side effect profile, but I would not bet on that until real-world prescribing data confirms it.</p><p>There is also a question nobody has answered yet. Daily oral dosing produces a different blood-level curve than weekly injection. Steady-state instead of peaks and troughs. That might mean smoother appetite suppression. It might also mean more cumulative GI exposure. Phase 3 discontinuation rates were in line with injectables, but Phase 3 populations are filtered and motivated. Primary care prescribing in 2026 and 2027 will tell us whether real-world tolerability holds.</p><h3>The Pricing Is the Most Interesting Part</h3><p>This is where the strategy becomes obvious.</p><p>Lilly is launching orforglipron at <a href="https://www.prnewswire.com/news-releases/fda-approves-lillys-foundayo-orforglipron-the-only-glp-1-pill-for-weight-loss-that-can-be-taken-any-time-of-day-without-food-or-water-restrictions-302731485.html">$149 per month for the lowest dose</a> through LillyDirect self-pay, scaling up to roughly $399 for higher doses. With a commercial insurance savings card, eligible patients can pay as little as $25 per month. Medicare Part D patients may access it for $50 per month starting July 1 under the new GLP-1 coverage rules, if those rules survive.</p><p>Compare that to LillyDirect’s cash-pay Zepbound vials, which run $299 for the 2.5 mg starter dose and $449 for higher doses. Foundayo at $149 is meaningfully cheaper than Zepbound at $299. The $25 savings-card pricing for insured patients is aggressive in a way that tells you Lilly is targeting conversion of new patients who have not started treatment yet.</p><p>This is not a pill that exists to replace Zepbound for existing Zepbound patients. It exists to expand the GLP-1 market by another 5 to 10 million Americans who would not have started an injection. The manufacturing stockpile, the pricing, the brand investment, all of it is pointed at volume.</p><h3>Where the Wegovy Pill Fits</h3><p>Novo’s <a href="https://www.managedhealthcareexecutive.com/view/foundayo-vs-oral-wegovy-13-things-you-should-know">Wegovy pill</a>, which got FDA approval in December 2025, is now in a difficult position. It produces about 13.6 percent weight loss, slightly more than orforglipron’s 12.4 percent. But it requires the morning fasting routine, the four-ounce water limit, the 30-minute wait. The Wegovy pill is a peptide, so its manufacturing remains expensive, and Novo cannot match Lilly on price the way Lilly can match itself.</p><p>The pill-to-pill comparison is not really about which one produces more weight loss. It is about whether you can build a daily fasting ritual into your morning. Some people can. Most people cannot, or do not, sustain it past month three. Real-world adherence is likely going to tilt heavily toward Foundayo even though the head-to-head trial efficacy slightly favors the Wegovy pill.</p><h3>Who Should Actually Switch</h3><p>Here is the honest list, after all of this.</p><p>You should consider orforglipron if you are in one of these groups:</p><ul><li>You have never started a GLP-1 and the needle was always the reason. Foundayo is now the easiest entry point in the entire category.</li><li>You are paying cash, are not tolerating the price of Zepbound or Wegovy, and would benefit from a $149 starting dose.</li><li>You travel constantly or have a living situation where weekly refrigeration of an injection pen is genuinely impractical.</li><li>You have been on the Wegovy pill, struggling with the morning fasting routine, and want a pill you can actually take consistently.</li><li>You are managing type 2 diabetes alongside weight and want a once-daily oral option with strong A1C data.</li></ul><p>You should probably stay where you are if:</p><ul><li>You are tolerating Zepbound and losing weight at a satisfying rate. The 8-point efficacy downgrade is real.</li><li>You are on tirzepatide for diabetes and your A1C and weight are both under control. Orforglipron is good but not better.</li><li>You have insurance coverage for an injectable and switching means leaving formulary.</li><li>You have a history of poor adherence to daily medications.</li></ul><p>The decision is genuinely personal. I am not a doctor, and what you do here is between you and a prescriber who knows your actual situation. If you are starting from scratch and want a quick read on which providers are already offering Foundayo, the <a href="https://glp1clinics.org/quiz">two-minute quiz</a> on glp1clinics.org will match you against the telehealth platforms that currently carry it.</p><h3>What I Am Watching</h3><p>Three things will tell us how this drug actually plays out over the next year.</p><p>The first is real-world adherence. If 12-month continuation rates run materially higher than what we see with injectables, the small efficacy gap is going to look very different in aggregate. A patient who stays on Foundayo for two years at 12 percent weight loss outperforms a patient who quits Zepbound at month four after 8 percent.</p><p>The second is manufacturing impact on the rest of the category. If Lilly can produce orforglipron at the scale the stockpile suggests, the pressure on Novo and on the compounded GLP-1 market is going to be significant. Compounded semaglutide pricing only makes sense as long as branded injectables remain expensive and rationed. A $149 small-molecule pill with full FDA approval is a new floor.</p><p>The third is whether the Medicare and Medicaid pricing actually holds. The $50 Medicare Part D number depends on the GLP-1 coverage rules <a href="https://www.kff.org/medicare/issue-brief/medicare-coverage-of-anti-obesity-drugs/">CMS has been negotiating</a> being finalized. Those rules have been a moving target for two years. If they hold, orforglipron becomes the first GLP-1 that elderly Americans on fixed incomes can actually afford. If they do not, the $149 self-pay floor still expands access more than any GLP-1 that has launched before.</p><h3>The Take</h3><p>Orforglipron is not Zepbound in pill form. The marketing copy will tell you it is. The trial data tells you it is somewhere between the Wegovy pill and the Wegovy injection on efficacy, with the easiest dosing routine of any GLP-1 ever approved, at a price that meaningfully undercuts the injectable category.</p><p>That combination is going to expand the addressable patient population significantly. It is not going to replace tirzepatide for people who are already doing well on tirzepatide. For an honest comparison of where the injectable class still wins, the <a href="https://glp1clinics.org/blog/zepbound-vs-wegovy">Zepbound versus Wegovy breakdown</a> is the right starting point. For a lot of people who have never started treatment because the needle was a no, this is the moment that changes.</p><p>The pill is not better. The pill is just easier. For some patients, easier is the entire game.</p><p><em>RC Nelson covers GLP-1 medications, weight loss science, and the business of healthcare. For more evidence-based breakdowns, follow at </em><a href="https://glp1clinics.org/"><em>glp1clinics.org</em></a><em>.</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=e21aef5d48af" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Novo’s CagriSema “Disappointed.” The Trial Data Is Way Better Than the Market Thinks.]]></title>
            <link>https://medium.com/@robertchristos/novos-cagrisema-disappointed-the-trial-data-is-way-better-than-the-market-thinks-96722c76fe27?source=rss-a810eec1c502------2</link>
            <guid isPermaLink="false">https://medium.com/p/96722c76fe27</guid>
            <category><![CDATA[pharma]]></category>
            <category><![CDATA[glp-1]]></category>
            <category><![CDATA[weight-loss]]></category>
            <category><![CDATA[novo-nordisk]]></category>
            <category><![CDATA[health]]></category>
            <dc:creator><![CDATA[Robert Christos Nelson]]></dc:creator>
            <pubDate>Sat, 09 May 2026 01:16:14 GMT</pubDate>
            <atom:updated>2026-05-09T01:16:14.534Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*bAztDWAHtV2wtXYpcwRDfg.png" /></figure><p><em>Wall Street decided in twenty minutes that Novo Nordisk’s next weight loss drug had failed. They were reading the wrong number. Here’s what the data actually says, and why this is still the most important molecule in the GLP-1 pipeline.</em></p><p>A reader emailed me two weeks ago asking if she should “wait for the new Wegovy” before starting GLP-1 treatment. She’d seen a YouTube video that called CagriSema “a flop” and another one calling it “the next breakthrough.” She asked, reasonably, which one was right.</p><p>Both are wrong. And the way they’re wrong tells you something useful about how to read drug-trial news.</p><p>On December 20, 2024, Novo Nordisk released the topline results from <a href="https://clinicaltrials.gov/study/NCT05567796">REDEFINE-1</a>, the Phase 3 trial of CagriSema in adults with obesity. The headline number was 22.7 percent mean weight loss at 68 weeks. By any historical standard for an obesity medication, that is a great result. It beats Wegovy. It is roughly tied with Zepbound. It is in the same neighborhood as bariatric surgery for a meaningful subset of patients.</p><p>And Novo’s stock dropped almost twenty percent in a single trading day.</p><p>The collapse happened because Wall Street had spent two years pricing in something larger than 25 percent. The expectation was that CagriSema would beat tirzepatide, that Novo would reclaim the obesity-drug crown from Eli Lilly, and that the next phase of the GLP-1 era would be Novo’s again. Twenty-two-point-seven did not clear that bar. The headlines that afternoon called it a disappointment. CNBC ran chyron after chyron about “the failed obesity drug.” A few biotech analysts called it dead on arrival.</p><p>I have spent enough time reading the actual REDEFINE-1 data, the ongoing <a href="https://clinicaltrials.gov/study/NCT05669599">REDEFINE-2 diabetes trial</a>, and the underlying pharmacology of cagrilintide to tell you that this read is wrong. It is wrong in a way that matters for patients who are trying to figure out whether to start treatment, switch treatment, or wait for what’s coming. So I want to walk through what CagriSema actually is, what the trial actually showed, why the trial design hurt the topline number more than the drug deserved, and what this likely means for the next eighteen months of obesity medicine.</p><h3>What CagriSema Actually Is</h3><p>CagriSema is two molecules in one weekly injection. The first is semaglutide, the same active ingredient that powers Ozempic and Wegovy. You already know that one. It’s a GLP-1 receptor agonist that mimics the body’s satiety hormone, slows gastric emptying, and dampens appetite signals in the brain. <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2032183">STEP-1</a>, the trial that got Wegovy approved, posted about 14.9 percent mean weight loss at 68 weeks. That’s the baseline you should anchor on.</p><p>The second is cagrilintide. This is the molecule almost nobody outside the obesity-medicine community knew about until two years ago, and it is the entire reason CagriSema exists.</p><p>Cagrilintide is a long-acting analog of amylin, a pancreatic hormone that gets released alongside insulin every time you eat. Amylin’s job is to coordinate post-meal satiety, slow gastric emptying, and tell your body that food has arrived and it can stop signaling hunger. The shorter-acting amylin analog, pramlintide, has been on the market for diabetes since 2005 under the brand <a href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=021332">Symlin</a>. Pramlintide works, but it requires injection at every meal, which is enough friction that almost nobody uses it.</p><p>Cagrilintide is the engineering fix. It’s amylin reformulated to last a full week, the same dosing cadence as semaglutide. The first <a href="https://pubmed.ncbi.nlm.nih.gov/34508652/">Phase 1b proof-of-concept paper</a> from Lau et al. in 2021 showed that combining cagrilintide with semaglutide produced additive weight loss in a small group, which is what greenlit the Phase 3 program. Combine it with semaglutide in one pen, and you have a weekly injection that hits two distinct satiety pathways at the same time. That is the thesis. Two satiety levers, pulled together, should produce more weight loss with less downside than either lever alone.</p><p>That thesis is also the reason CagriSema matters even after a “disappointing” headline. The mechanism is not incremental. Tirzepatide, the molecule in Mounjaro and Zepbound, combines GIP and GLP-1 agonism. Retatrutide adds glucagon receptor activity to that mix. Both are variations on hitting more receptors in the gut-brain axis. Cagrilintide is something different. It hits a parallel system that GLP-1 doesn’t touch directly. If you believe, as most obesity researchers do, that long-term weight management is going to require pulling multiple independent levers rather than just turning one lever harder, CagriSema is on the right side of that future. I wrote about how the existing options compare on mechanism in a longer piece on <a href="https://glp1clinics.org/blog/semaglutide-vs-tirzepatide-comparison">semaglutide versus tirzepatide</a> if you want the deeper version.</p><h3>What REDEFINE-1 Actually Showed</h3><p>The trial enrolled 3,417 adults with overweight or obesity, randomized them to CagriSema, semaglutide alone, cagrilintide alone, or placebo, and followed them for 68 weeks. The primary endpoint was mean percentage change in body weight. The headline result was a 22.7 percent reduction in the CagriSema arm.</p><p>That is the number that everyone quoted. It is also the wrong number to anchor on if you want to understand the drug.</p><p>The first thing that gets buried in topline summaries is the comparison to monotherapy. Semaglutide alone produced about 16 percent weight loss in this same trial, slightly above the STEP-1 number because the population was different. Cagrilintide alone produced about 12 percent. The combination produced almost 23 percent. That additivity matters. It tells you the two mechanisms are not redundant. If they were stepping on each other, you would see overlap and diminishing returns, not summation.</p><p>The second thing that gets buried is what happened with dosing. Roughly 58 percent of the CagriSema arm reached the highest planned dose by week 68. The remaining 42 percent stayed at lower doses for tolerability reasons or were stepped down because of side effects. That distribution drags the mean down. The patients at the full dose for the longest stretch posted weight loss numbers that were noticeably above 22.7 percent, with subgroup analyses in the 25 to 27 percent range, which would put the drug at parity with or slightly ahead of tirzepatide in <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2206038">SURMOUNT-1</a>. The mean is not the maximum. The mean reflects the entire titration experience, including the patients who never made it to full strength.</p><p>This matters because in real-world prescribing, providers and patients adjust to tolerability. Nobody is going to be force-titrated past their nausea threshold. The number that more closely resembles what a tolerating patient at the full dose actually experiences is the higher end of that distribution, not the trial-wide mean.</p><p>The third thing that gets buried is what happened to body composition. CagriSema, like every GLP-1, drives some lean-mass loss alongside fat loss. The cagrilintide component appears to slightly favor fat loss over lean mass loss compared to semaglutide alone. The data on this is preliminary and the effect is not enormous, but it is in the right direction. Given how much attention is now going to muscle preservation in long-term GLP-1 use, even a modest tilt toward more selective fat loss is meaningful.</p><h3>The REDEFINE-2 Diabetes Story Is Better Than People Realize</h3><p>While everyone was busy declaring CagriSema dead based on REDEFINE-1, the <a href="https://clinicaltrials.gov/study/NCT05669599">REDEFINE-2 trial</a> was reading out separately. REDEFINE-2 ran CagriSema in adults with type 2 diabetes and obesity. The topline reported around 13.7 percent weight loss alongside meaningful A1C reduction.</p><p>For diabetics, 13.7 percent is a strong number. Patients with type 2 diabetes consistently lose less weight on every GLP-1 medication than non-diabetic patients on the same dose. The difference comes down to insulin physiology and a slower metabolic response. Tirzepatide in SURPASS-2 produced about 11 to 12 percent weight loss in the diabetic population. So CagriSema in diabetics is performing at or slightly above tirzepatide in the same population. Nobody is talking about that, because the obesity headline absorbed all the oxygen.</p><p>If CagriSema gets approved as a weight loss medication and ends up indicated for diabetics with obesity, the prescribing reality is going to be that it competes very directly with Mounjaro for that population. Diabetics who can’t tolerate tirzepatide, or whose insurance prefers another option, will have a real second choice that hits comparable weight loss with a different side effect profile.</p><h3>Why Novo Has to Make This Work</h3><p>The strategic context is important and almost never explained in patient-facing coverage. Eli Lilly is currently winning the obesity drug market. Tirzepatide outperforms semaglutide on weight loss in head-to-head data. <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2416394">SURMOUNT-5</a>, the recent direct comparison trial published in the New England Journal of Medicine in May 2025, reported that tirzepatide produced roughly 47 percent more weight loss than semaglutide at peak doses. Insurance coverage is starting to follow that data. Prescribers are starting to default to Zepbound. I broke down the practical patient-side implications in an earlier piece on <a href="https://glp1clinics.org/blog/zepbound-vs-wegovy">Zepbound versus Wegovy</a>. Novo, which spent the last decade dominating GLP-1 with Ozempic and Wegovy, is watching its market share erode in real time.</p><p>CagriSema is Novo’s answer. Not retatrutide, which is Lilly’s. Not orforglipron, which is also Lilly’s. CagriSema is the molecule Novo has been planning to launch as the second-generation Wegovy since at least 2021. It is the pipeline drug that has to work, because if it doesn’t, Novo’s obesity story for the late 2020s is essentially “compete on price with whatever Lilly puts out next.” That is not where any pharmaceutical company wants to be.</p><p>Which means Novo will absolutely file with the FDA. Approval is expected around the second half of 2026. Pricing will probably mirror Wegovy at first, in the $1,300 to $1,400 per month cash-pay range, with insurance and PBM coverage taking another year to settle. The launch will come with a marketing budget that makes the original Ozempic campaign look modest.</p><p>None of that depends on whether CagriSema beat tirzepatide on a head-to-head topline. It only depends on the drug working well enough to be approved, which the data clearly supports. The 22.7 percent headline is not a problem for FDA approval. It is only a problem for stock-price expectations.</p><h3>What This Means If You’re a Patient</h3><p>The reader who emailed me asked whether she should wait. The answer for almost everyone is no, you should not wait.</p><p>If you have access to a GLP-1 medication today, whether that’s Wegovy, Zepbound, Mounjaro, or compounded semaglutide or tirzepatide, and you are a candidate for treatment, starting now is almost always the right call. Every month you delay is a month you lose to additional weight gain, additional time spent at higher metabolic risk, and additional exposure to the conditions that GLP-1 medications most help with. Waiting for a drug that is not yet approved, will not be on insurance formularies for at least a year after launch, and will cost more than what you currently have access to is rarely the right move. If you don’t already have a prescriber, the fastest path is usually a telehealth provider, and I keep an updated <a href="https://glp1clinics.org/telehealth-providers">side-by-side comparison of the major platforms</a> with current pricing and dosing options.</p><p>The exception is if you are paying entirely cash, you have failed two existing GLP-1s for tolerability reasons, and you specifically suspect that nausea or appetite-suppression intensity is your limiting factor. In that narrow case, the cagrilintide component might offer a different tolerability profile worth waiting for. But even there, “waiting” probably means starting a current option and switching later, not sitting on the sidelines for twelve to eighteen months.</p><p>The patients I think CagriSema will most help, when it arrives, are:</p><ul><li>Diabetics with obesity who haven’t tolerated tirzepatide and need a different mechanism</li><li>Patients who plateaued on Wegovy and don’t respond to a switch to Zepbound</li><li>Patients who specifically lost too much lean mass on semaglutide or tirzepatide</li><li>Patients whose insurance ends up preferring a Novo product over a Lilly product because of rebate structure</li></ul><p>That last bullet is going to matter more than people realize. Pharmacy benefit managers do not pick which drug works best. They pick which drug their rebate structure favors. If Novo cuts a better deal with the major PBMs, CagriSema will be the formulary-preferred option for millions of patients regardless of comparative efficacy. The same dynamic is why Wegovy is still on more formularies than Zepbound today, despite Zepbound’s better data.</p><h3>What to Watch For</h3><p>Three signals will tell you how CagriSema actually plays out.</p><p>The first is the FDA approval letter and the indication language. If CagriSema gets approved with an indication for cardiovascular outcomes, similar to what Wegovy received after the SELECT trial, it becomes a Medicare-eligible drug under the new coverage rules. That changes the entire commercial equation.</p><p>The second is real-world tolerability data after launch. Phase 3 trial populations are filtered. The patients who actually start the drug in primary care offices in 2026 and 2027 will tell you whether the cagrilintide component genuinely produces a smoother titration than semaglutide alone. If the discontinuation rate at week 16 is meaningfully lower than what we see with Wegovy, CagriSema becomes the better practical option for most patients even if the peak weight loss is not the best in class.</p><p>The third is what Novo charges. If CagriSema launches at a meaningful premium to Wegovy, Lilly will use that as a marketing opening. If it launches at price parity, the insurance dynamics will likely tilt toward CagriSema for Novo-preferred plans within a year. I keep a running breakdown of where every current GLP-1 lands on cash-pay, insurance, and compounded pricing in the <a href="https://glp1clinics.org/cost-guide">cost guide</a>, and I’ll update it the day CagriSema’s pricing is announced.</p><p>None of those three signals had anything to do with whether the topline weight loss number was 22.7 versus 25.</p><h3>The Lesson</h3><p>Stock-market reactions to drug-trial readouts are about expectations, not patients. The market priced CagriSema as if it had to beat tirzepatide on the single headline number, and when it didn’t, the market priced it as if the drug had failed. Neither of those positions has anything to do with the actual clinical question of whether the drug helps the patients it gets prescribed to. It clearly does. It will get approved. It will get prescribed. It will help millions of people.</p><p>The “disappointing” framing exists because the people writing it have to write something that justifies a price move. The actual data justifies measured optimism, and a clearer eye on what the drug is for and who it is for. If you want to look smarter than the market, read the dose-response curves and the subgroup analyses. The interesting numbers are not the ones the headlines run.</p><p>If you are trying to lose weight today, get on a GLP-1 today. If you are trying to figure out which drug your prescriber will be talking about in 2027, the answer is probably this one, regardless of what Wall Street decided in twenty minutes on a Friday afternoon in December. Find a clinic that prescribes the current generation at <a href="https://glp1clinics.org/glp1-clinics">glp1clinics.org</a>.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=96722c76fe27" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Your GLP-1 Isn’t Causing Your Hair Loss. Here’s What Actually Is, and What to Do About It.]]></title>
            <link>https://medium.com/@robertchristos/your-glp-1-isnt-causing-your-hair-loss-here-s-what-actually-is-and-what-to-do-about-it-7c5e5a428bb9?source=rss-a810eec1c502------2</link>
            <guid isPermaLink="false">https://medium.com/p/7c5e5a428bb9</guid>
            <category><![CDATA[health]]></category>
            <category><![CDATA[hair-loss]]></category>
            <category><![CDATA[wegovy]]></category>
            <category><![CDATA[glp-1]]></category>
            <category><![CDATA[zepbound]]></category>
            <dc:creator><![CDATA[Robert Christos Nelson]]></dc:creator>
            <pubDate>Wed, 06 May 2026 22:59:08 GMT</pubDate>
            <atom:updated>2026-05-06T22:59:08.480Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*UekV5TJipRoWNelPo_wj4w.png" /></figure><p><em>The hair shedding starts around month four, peaks at five to seven, and resolves by month twelve for almost everyone. The supplement industry is selling you the wrong fix.</em></p><p>A reader sent me a photo last week. It was the bottom of her shower drain, covered in dark hair. She was in month five of Wegovy, down 28 pounds, feeling better than she had in years, and now seriously considering quitting because her hair was, in her words, “falling out in handfuls.” Her PCP had told her it was probably the medication and that she should consider stopping. Her aesthetician had sold her a $90 bottle of marine collagen and a bag of “GLP-1 hair vitamins.” A coworker told her to switch to Zepbound because “tirzepatide doesn’t do that.” Her hairdresser was, of course, devastated.</p><p>I told her not to do any of those things. I told her she was experiencing the most well-documented, most predictable, most temporary side effect on the GLP-1 spectrum, and that almost everything she’d been told about it was wrong.</p><p>I’ve been writing about GLP-1 medications for a while, and the hair loss conversation is the one I see go off the rails most consistently. Patients panic. Prescribers shrug. The supplement industry feasts. And in the middle of all of that, the actual science of what’s happening is pretty boring and pretty knowable, and almost nobody is communicating it clearly.</p><p>So let me try.</p><h3>It’s Not the Drug. It’s the Weight Loss.</h3><p>Here’s the single most important sentence in this article: GLP-1 medications do not directly cause hair loss in any meaningful way. The hair shedding that patients experience is a downstream consequence of rapid weight loss itself, not the chemical action of semaglutide or tirzepatide on the body.</p><p>The technical name for what’s happening is telogen effluvium. It’s the most common form of diffuse hair shedding in adults, and it has been studied for decades, mostly in the context of post-pregnancy hair loss, post-bariatric surgery hair loss, post-illness hair loss, and rapid weight loss in general. The mechanism is the same regardless of the trigger.</p><p>Hair on your scalp cycles through three phases. Anagen is the growth phase, where 85 to 90 percent of the hair on a healthy head sits at any given time. Catagen is a brief transitional phase, less than 1 percent. Telogen is the resting phase, which lasts a few months before that hair sheds and is replaced by new growth from the same follicle. In a normal scalp, this is a quiet, ongoing process. You shed 50 to 100 hairs a day and never notice.</p><p>What happens with telogen effluvium is that a significant body stressor pushes a much larger percentage of your hair, usually 10 to 30 percent, into the telogen phase all at once. The hairs sit there for two to three months. Then they shed together. That’s why the timing on GLP-1 patients is so eerily predictable. The body recognizes rapid weight loss, sustained calorie deficit, and the metabolic shifts that come with both as a stressor. The hair cycle responds within weeks. Two to three months later, the mirror notices.</p><p>This is why switching from Wegovy to Zepbound doesn’t fix the problem. The molecule isn’t the trigger. The weight loss is. As long as you’re losing weight at a meaningful rate, your body is signaling stress to the hair cycle, regardless of which receptor agonist you’re using to suppress your appetite.</p><p>The dermatology literature has known this for years. The triggering stressors are well-documented: rapid weight loss of more than 5 percent body weight in two months, sustained calorie deficits below 1,200 daily calories, low protein intake, iron deficiency, vitamin D deficiency, severe illness, surgery, childbirth, and major psychological stress. Read that list again. Almost every GLP-1 patient hits at least three of those in the first few months of treatment.</p><h3>What the Clinical Trials Actually Showed</h3><p>Let me give you the real numbers, because the conversation around hair loss has gotten unhinged.</p><p>In the STEP trials for semaglutide 2.4 mg, hair-related disorders were reported in approximately 3 percent of participants on the active drug versus 1 percent on placebo. That’s an absolute increase of 2 percentage points. Roughly two extra people out of every hundred reported hair changes compared to a placebo group that was also losing some weight from lifestyle counseling.</p><p>For tirzepatide, the SURMOUNT-1 trial reported alopecia in about 5.7 percent of participants on the highest 15 mg dose. Higher than semaglutide, but the SURMOUNT-1 cohort was also losing more weight on average, which is consistent with the rapid-weight-loss-causes-shedding theory.</p><p>For comparison, the rate of telogen effluvium in post-pregnancy women is somewhere between 40 and 50 percent. The rate after bariatric surgery is between 50 and 70 percent in the first year. The rate after a major illness or surgery is around 30 to 50 percent.</p><p>So when you read social media posts framing GLP-1 hair loss as some catastrophic, drug-specific phenomenon, the actual incidence is roughly an order of magnitude lower than what most pregnant women experience and never make a public issue of. That’s not to dismiss the experience. Hair loss is psychologically rough regardless of incidence rate. But context matters, and the context here has been completely lost.</p><p>For the record, I keep updated breakdowns of <a href="https://glp1clinics.org/safety">GLP-1 safety considerations</a> that cover this and the rest of the side effect profile in more depth.</p><h3>The Realistic Timeline (and Why “Realistic” Matters)</h3><p>Here’s what actually plays out, based on the published data and what I’ve seen reading through hundreds of patient accounts on Reddit, in clinic interview transcripts, and in the dermatology literature.</p><p><strong>Months 1 and 2:</strong> You’re losing weight rapidly. Your appetite has fallen off a cliff. Your protein intake has probably dropped along with everything else, even if you don’t realize it. Your hair looks fine. The cycle hasn’t responded yet because telogen effluvium has a built-in delay. The damage is being done now, but the symptom shows up later.</p><p><strong>Month 3:</strong> First noticeable shedding. Usually subtle. You see a few extra hairs on your pillow. The brush has more in it than usual. Some people start to wonder. Most people shrug it off.</p><p><strong>Months 4 and 5:</strong> Shedding becomes obvious. This is when patients bring it up at the prescribing visit. The shower drain. The hair tie that snaps three times in a row. The hair in your morning coffee. The pony tail that feels suddenly thinner. People start photographing their parts and comparing month-to-month.</p><p><strong>Months 5 through 7:</strong> Peak shedding. This is the window where most patients seriously consider stopping the medication, and where bad clinical advice does the most damage. Hair density visibly thinner, especially at the crown and temples. The instinct to panic is at its highest. The supplement industry’s marketing machine is firing on all cylinders.</p><p><strong>Months 7 through 9:</strong> Shedding slows dramatically. New growth becomes visible, often as fine baby hairs along the hairline. Most patients don’t notice this stage as much because the new growth is delicate and short, but it’s the first sign of recovery.</p><p><strong>Months 9 through 12:</strong> Recovery. Hair density returns to baseline or close to it for the vast majority of patients. The new hair is coming in at full thickness, the cycle has normalized, and the dramatic phase is over.</p><p><strong>Beyond month 12:</strong> If shedding hasn’t significantly improved by the one-year mark, that’s the threshold where you stop attributing it to GLP-1-related telogen effluvium and start working it up as a separate problem. Iron deficiency, thyroid dysfunction, androgenic alopecia worsening under stress, scarring alopecia, and a few other rare conditions can produce persistent shedding past 12 months. That’s a dermatologist visit, not a supplement aisle.</p><p>The timing varies. Patients losing weight faster experience earlier and more severe shedding. Patients losing slower often barely notice it. The single biggest predictor of how bad your hair loss will be is how fast you’re losing weight, and that’s also the thing you have the most direct control over.</p><h3>Three Things That Actually Help</h3><p>Here’s the part of the article that the supplement industry doesn’t want you to read. The actual evidence-based interventions for GLP-1 hair shedding are unsexy, free or nearly free, and don’t come in a branded bottle.</p><p><strong>1. Hit a real protein floor.</strong> The single biggest mistake patients make on GLP-1s is dramatically undereating protein because they’re not hungry. This is the closest thing to a universal rule in this entire space. Hair is keratin. Keratin is a protein. When your body is short on amino acids, hair maintenance is one of the first things it deprioritizes, because hair is metabolically expensive and not strictly required for survival.</p><p>The functional floor is approximately 0.7 to 1.0 grams of protein per pound of goal body weight per day. For someone targeting 160 pounds, that’s 112 to 160 grams of protein daily. On a GLP-1, getting there is genuinely hard. You will not feel like eating that much. You have to plan it. Greek yogurt at breakfast (around 25 grams). A 30-gram protein shake mid-morning. A protein-forward lunch with chicken or fish or tofu (around 30 grams). Dinner planned around the meat or fish first, vegetables second, carbs third (another 35 to 45 grams).</p><p>If that sounds like too much engineering, you’re right. It is. But it’s also the difference between barely shedding and shedding aggressively. The post-bariatric surgery data on this is unambiguous. Adequate protein intake significantly reduces the severity and duration of telogen effluvium. Inadequate protein intake makes it worse.</p><p><strong>2. Get your labs checked at month three.</strong> A basic CBC plus a ferritin level plus a vitamin D level is cheap, often covered by insurance, and most GLP-1 patients should be getting them anyway as part of competent monitoring. Ferritin below 30 ng/mL and vitamin D below 30 ng/mL both correlate strongly with worse hair shedding in the dermatology literature, and both respond to supplementation when actually deficient.</p><p>Note the qualifier. If your labs come back normal, additional supplementation does not help. The body excretes excess vitamins it doesn’t need. There’s no benefit to flooding your system with iron when your ferritin is already at 60. The “more is better” model that the supplement industry promotes is actively wrong here. You want to find the deficits and correct them, not stack a bunch of pills hoping something works.</p><p>If your prescriber won’t order these labs, that tells you something about your prescriber. Find one who will. The <a href="https://glp1clinics.org/quiz">90-second provider quiz</a> on my site is one way to match with a clinic that actually monitors patients between visits.</p><p><strong>3. Slow down the rate of weight loss.</strong> If you’re losing more than 1 percent of your body weight per week, your body is reading that as a hard stress signal, and your hair cycle is responding accordingly. A 200-pound person losing more than 2 pounds a week is in the high-stress zone. Slowing down to 0.5 to 0.75 percent per week, which is 1 to 1.5 pounds for that same person, is associated with significantly less hair shedding in the bariatric surgery literature, where the same telogen effluvium mechanism applies.</p><p>Practically, slowing down means staying at a lower titration step longer or eating slightly more. Especially of protein. Yes, your total weight loss timeline gets longer. Yes, you might be on the medication for an extra few months to reach the same endpoint. That tradeoff, slower loss for less hair shedding, is one most patients gladly take once they understand it’s an option.</p><p>One more honorable mention. Topical minoxidil 5 percent, applied once or twice daily, is reasonable to add at month 6 or 7 if shedding is still severe and visible. It won’t help with the underlying telogen effluvium, but it accelerates recovery once shedding stops by extending the anagen phase of new growth. It’s over-the-counter, costs about $20 a month, and is one of the few hair products with actually robust clinical evidence behind it.</p><h3>What the Supplement Industry Sells You (and Why It Doesn’t Work)</h3><p>I have to address this directly because it’s where the most money is being wasted and the most patients are being misled.</p><p>The supplement industry has built an entire product category around GLP-1 hair loss. “GLP-1 hair vitamins.” “Ozempic hair support.” “Tirzepatide recovery formula.” Almost all of these are some combination of biotin, marine collagen, hair-skin-and-nails multivitamins, and various proprietary blends with names that sound vaguely scientific.</p><p>Let me go through them.</p><p><strong>Biotin.</strong> Biotin deficiency is genuinely rare in adults eating any reasonable diet. Almost nobody on a GLP-1 is biotin-deficient. The studies showing biotin helps hair loss are almost exclusively in patients with documented biotin deficiency, which is a different population. Supplementing biotin if you’re not deficient does essentially nothing for your hair, and high-dose biotin can actually interfere with thyroid lab tests and other diagnostics, which is a real and underappreciated problem.</p><p><strong>Marine collagen.</strong> The pitch is that you’re consuming the building blocks of hair. The reality is that collagen, like all proteins, gets broken down into individual amino acids in your gut. Your body doesn’t reassemble those amino acids into hair just because they came from a collagen source. They go into the general amino acid pool and get used wherever the body needs them. The protein content of a typical marine collagen serving is also low, around 10 grams, which is a fraction of what you should be eating from regular food anyway. You’re paying $40 a month for what amounts to slightly expensive whey.</p><p><strong>Hair, skin, and nails multivitamins.</strong> These are essentially regular multivitamins with extra biotin and a tiny dose of iron, sold at significant markup. If you’re deficient in something, a regular multivitamin will fix it just as well at a quarter of the price. If you’re not deficient, neither one helps.</p><p><strong>Proprietary blends.</strong> Run from these. The “proprietary blend” label exists specifically so manufacturers don’t have to disclose how much of each ingredient is in the bottle. Almost always, the active ingredients are present in tiny amounts well below the doses studied in research. You’re paying for marketing.</p><p>The only supplement worth taking unconditionally on a GLP-1 is a protein source, and even that is almost always better gotten from food. Cottage cheese is more bioavailable than any pill on the market and costs less.</p><p>If you want to see how this kind of supplement marketing intersects with the broader telehealth GLP-1 space, my <a href="https://glp1clinics.org/blog/glp1-supplements-truth">deeper breakdown of GLP-1 supplements</a> goes into the specific products and the studies they cite.</p><h3>What Bad Clinical Advice Looks Like</h3><p>I want to spend a minute on this because patients are being failed by their providers in predictable ways, and recognizing the pattern can save you a lot of grief.</p><p>“Switch to Zepbound, that one doesn’t cause hair loss.” Wrong. Both medications cause hair shedding through the same rapid-weight-loss mechanism. Switching molecules will not help.</p><p>“Just stop the medication for a month.” Stopping the medication helps only because it stops the weight loss, which is the actual trigger. But it also undoes the metabolic progress you’ve made, and most patients regain quickly when they pause GLP-1 therapy. There are better options that don’t require stopping treatment.</p><p>“It’s just hormones.” Telogen effluvium isn’t hormonal in the GLP-1 context. It’s nutritional and stress-mediated. Calling it hormonal is medically incorrect and leads to the wrong interventions.</p><p>“Try our compounded hair regrowth blend.” Compounded hair products are not FDA-reviewed for efficacy. Most are some combination of minoxidil, finasteride, and proprietary additives, sold at significant markup. Topical 5 percent minoxidil from any pharmacy is better and cheaper.</p><p>“Have you tried red light therapy?” Low-level laser therapy has some evidence for androgenic alopecia, the genetic male-pattern or female-pattern baldness. It does not have meaningful evidence for telogen effluvium. The mechanism doesn’t apply.</p><p>“It’s permanent for some people.” This is the worst one because it’s almost always wrong and it scares patients into stopping their medication unnecessarily. Telogen effluvium is, by definition, reversible. The follicles are not damaged. They are resting. Persistent hair loss past 12 months is a different condition that needs a separate workup, not a reason to assume the GLP-1 caused permanent damage.</p><h3>The Practical Playbook</h3><p>Alright. You’re in month four, you’re shedding, and you want to know what to actually do this week. Here’s the playbook I’d give a friend.</p><p><strong>Week one: assess the rate.</strong> Pull your weight log from the last six weeks. Calculate your weekly average loss as a percentage of body weight. If it’s over 1 percent per week, that’s your first lever. Talk to your prescriber about staying at your current dose longer, eating more, or both. Slower is better here. You will get to the same destination.</p><p><strong>Week two: lock down protein.</strong> Buy a kitchen scale. Weigh your meals for one week, just to know. Track your protein intake honestly. If you’re under 1 gram per kilogram of current body weight, you have a protein problem before you have a hair problem. Add a daily protein shake, a Greek yogurt, two extra eggs, whatever you can sustainably hit. Aim higher, ideally toward 0.7 to 1.0 grams per pound of goal weight.</p><p><strong>Week three: get the labs.</strong> Order a CBC, ferritin, vitamin D, and TSH. If your prescriber won’t order them through your insurance, services like Quest Direct or LabCorp’s OnDemand will run all four for around $80 to $120 out of pocket. Worth it. If anything comes back deficient, treat the deficit specifically. If everything is normal, that rules out the most common workup-able causes and gives you peace of mind.</p><p><strong>Week four: stop the supplements.</strong> If you’re currently on biotin, marine collagen, or hair-skin-and-nails vitamins, stop. They aren’t helping. Take that money and put it toward better protein sources or a gym membership.</p><p><strong>Month two: add minoxidil if needed.</strong> If shedding is still severe past month six and visibly affecting density, add topical 5 percent minoxidil. It won’t reverse the shedding, but it will speed up the regrowth phase. Generic minoxidil from any pharmacy works just as well as brand-name Rogaine. Start once daily, work up to twice if tolerated.</p><p><strong>Month three onward: ride it out.</strong> The shedding will slow. The new growth will come in. The instinct to panic and try something dramatic is at its highest exactly when patience is the right answer. If you’ve done the protein, the labs, and the rate adjustment, you’ve done what the data supports. The rest is time.</p><h3>When It’s Not Telogen Effluvium</h3><p>Most GLP-1 hair shedding is straightforward. A small fraction of patients have something else going on, and recognizing the difference saves you months of wrong treatments. Red flags worth working up with a dermatologist:</p><ul><li>Shedding has not significantly improved by month 12.</li><li>You see patches of complete hair loss, not just diffuse thinning. That’s alopecia areata, an autoimmune condition that’s treated very differently.</li><li>You have a personal or family history of androgenic alopecia, the male or female pattern baldness, that may be unmasking under the rapid-weight-loss stress and accelerating beyond what would have happened otherwise.</li><li>Eyebrow or eyelash thinning along with scalp shedding suggests thyroid dysfunction, which has a completely separate workup and treatment.</li><li>New scalp itching, redness, tenderness, or visible scarring suggests inflammatory or scarring alopecia, both of which need urgent dermatology evaluation because they can become permanent if untreated.</li><li>Hair pulling out painlessly with the root attached, in patches, especially in someone under chronic stress, can indicate trichotillomania, which is a behavioral condition.</li></ul><p>These are unusual but worth ruling out if the timeline doesn’t match the standard telogen effluvium pattern above. A good dermatologist will examine the scalp, possibly do a hair pull test, and order targeted labs based on what they see. That visit is more useful than a year of supplement experimentation.</p><h3>The Honest Bottom Line</h3><p>Most people lose some hair on a GLP-1. Most people get it back within a year. Most people are eating too little protein and could fix half the problem with a 100-gram daily protein floor. Switching medications doesn’t help because the trigger is the weight loss itself. Stopping the medication helps only because it stops the weight loss, and most patients don’t actually want to stop losing weight, which is why they were on the medication in the first place.</p><p>The reasonable response, in the order I’d recommend it: protein floor, lab check, slow the rate of loss, optionally add minoxidil after month six, and wait it out. If you’re past month 12 with no improvement, that’s when you call a dermatologist. Until then, the medication is doing exactly what you wanted it to do. The hair will catch up. It almost always does.</p><p>The worst thing you can do is panic and stop a medication that’s working over a side effect that’s temporary. The second worst thing you can do is pour money into supplements that have never been shown to help the actual mechanism at play here. The third worst thing you can do is take medical advice from your aesthetician or a TikTok creator with a coupon code.</p><p>Your hair is not abandoning you. It’s resting. And in nine to twelve months, the vast majority of it is coming back, often thicker than before because the new follicles are entering an active growth phase together. The drain looks alarming. The forecast is reassuring. Trust the data more than the panic, and use the playbook.</p><p><em>RC Nelson covers GLP-1 medications, weight loss science, and the business of healthcare. For more evidence-based breakdowns, follow at </em><a href="https://glp1clinics.org/"><em>glp1clinics.org</em></a><em>.</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=7c5e5a428bb9" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[“Ozempic Babies” Are Real. The Science Is Way More Interesting Than the Headlines.]]></title>
            <link>https://medium.com/@robertchristos/ozempic-babies-are-real-the-science-is-way-more-interesting-than-the-headlines-42c975bc202f?source=rss-a810eec1c502------2</link>
            <guid isPermaLink="false">https://medium.com/p/42c975bc202f</guid>
            <category><![CDATA[mens-health]]></category>
            <category><![CDATA[weight-loss]]></category>
            <category><![CDATA[glp-1]]></category>
            <category><![CDATA[health]]></category>
            <category><![CDATA[fertility]]></category>
            <dc:creator><![CDATA[Robert Christos Nelson]]></dc:creator>
            <pubDate>Sat, 02 May 2026 19:44:32 GMT</pubDate>
            <atom:updated>2026-05-02T19:44:32.390Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*fkBSFyEM36mqXK4CSzoA6g.png" /></figure><p>Forget the surprise-pregnancy memes. The actual story is about how a weight loss drug is turning out to be one of the more effective male fertility treatments we have.</p><p>“Ozempic babies” started as a women’s story. The headlines were about birth control efficacy dropping in women who were losing weight rapidly on semaglutide and tirzepatide. That part is real, and it’s worth knowing about if you’re on a GLP-1 and not actively trying to get pregnant.</p><p>But that’s not the whole story. Buried under the surprise-pregnancy memes is a much more interesting development that almost no general-audience publication has covered well: GLP-1s appear to be one of the more effective male fertility interventions we have for a specific subset of men. And the data has been quietly piling up.</p><p>I started looking into this after seeing a urologist’s tweet thread that claimed semaglutide “outperformed clomiphene” in his clinic for men with obesity-related low testosterone. That’s a strong claim. Clomiphene is the off-label workhorse for boosting testosterone in younger men who want to preserve fertility. So I went looking for the actual research.</p><h3>The Mechanism Is Almost Embarrassingly Simple</h3><p>Before getting to the data, here’s the underlying biology, because it makes everything else make sense.</p><p>Obesity causes a specific kind of low testosterone called metabolic hypogonadism. The mechanism: fat tissue contains an enzyme called aromatase that converts testosterone into estrogen. The more fat tissue you have, especially visceral abdominal fat, the more aromatase activity, the more testosterone gets converted into estrogen, and the lower your free testosterone runs. The estrogen then signals the hypothalamus to dial down the production of luteinizing hormone, which is what tells the testes to make more testosterone in the first place. The whole feedback loop gets suppressed by being overweight.</p><p>Add in inflammation, insulin resistance, sleep apnea, and the metabolic chaos that tends to ride along with obesity, and you get a system that’s actively producing less testosterone and converting more of what it does make into the wrong hormone for male fertility.</p><p>So what happens when you remove the fat? You’d expect aromatase activity to drop, the feedback loop to recover, testosterone to rise, and sperm parameters to improve. That’s the hypothesis. The question has been whether it actually plays out that way in the real world.</p><h3>What the Studies Actually Show</h3><p>The clearest signal so far comes from a <a href="https://www.urologytimes.com/view/aua-2025-glp-1-ras-could-improve-sperm-count-in-overweight-men">study presented at the American Urological Association meeting in 2025</a>. Researchers looked at overweight and obese men with low sperm counts who were prescribed GLP-1 receptor agonists. After treatment, sperm counts improved meaningfully, and 3% of men in the study group reached sperm counts in the normal range that hadn’t been there before treatment.</p><p>Three percent doesn’t sound like much, but for context, this is in a group where the baseline counts were specifically below normal and weight was the primary candidate cause. Getting back to fertile range from a clinically infertile baseline is a big functional jump. The 97% who didn’t reach normal still trended up.</p><p>A separate <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10820247/">narrative review in PMC</a> pulled together the existing data and found GLP-1 RA therapy was associated with significant increases in total testosterone, particularly among obese men and men with metabolic dysfunction. The bigger the baseline metabolic problem, the bigger the swing.</p><p>The strongest individual study to date was a 2025 randomized controlled trial of obese men with type 2 diabetes and hypogonadism. They got semaglutide 1 mg weekly for 24 weeks. At the end, the study group showed significant improvement in sperm morphology, which is one of the harder semen parameters to move with any intervention. Morphology tends to be stuck where it is. Moving it with a 6-month intervention is notable.</p><p>The <a href="https://www.frontiersin.org/journals/physiology/articles/10.3389/fphys.2024.1496416/full">Frontiers in Physiology review</a> from late 2024 summarized what we know across animal and human studies and reached basically the same conclusion: there’s strong mechanistic evidence and a growing pile of clinical data suggesting GLP-1s help spermatogenesis in obese men, while the picture is much less clear (and sometimes negative) in lean men.</p><p>Worth noting: most of these studies are small and short. We don’t have a 2,000-patient three-year RCT specifically designed to look at fertility outcomes. The signal is consistent. The certainty isn’t where it would be for a labeled indication.</p><h3>Where the Caution Comes In</h3><p>It’s not all upside. The same Frontiers review and a few earlier studies flagged that liraglutide, an older GLP-1, was associated in some patient cohorts with reduced sperm quality during active treatment. The encouraging part of that finding: sperm parameters mostly recovered after about five months off the drug. But not all the way back to baseline.</p><p>Whether that’s a liraglutide-specific quirk or a class effect we should be watching for in semaglutide and tirzepatide is genuinely unclear. The mouse and cell-line data on semaglutide so far has been clean, with <a href="https://link.springer.com/article/10.1007/s12020-025-04245-4">a 2025 paper in Endocrine showing no detrimental effect on sperm in mouse models or in human sperm cell lines</a>. But mouse models and cell lines aren’t the same as ten years of human follow-up.</p><p>The other unknown is whether the fertility benefit is from the GLP-1 itself or from the weight loss it causes. If it’s mostly the weight loss, then any meaningful weight loss intervention should produce similar effects. If it’s a direct GLP-1 receptor effect on testicular tissue, that would be more interesting and would suggest GLP-1s might help even men whose obesity is mild but whose hormones are still dragged down by it.</p><p>The animal data hints at some direct receptor activity in testicular tissue. But it’s early. I’d want a few more years of human data before I’d say with confidence that the effect is mostly direct rather than mostly secondary to weight loss.</p><h3>What This Means for Men Considering GLP-1s</h3><p>If you’re a man with obesity who’s also been diagnosed with low testosterone or borderline subfertility, this is a meaningfully different conversation than it would have been three years ago. Your endocrinologist or urologist is likely already aware of this data, but plenty of primary care doctors aren’t. It’s worth asking specifically.</p><p>The standard alternatives for obesity-related low testosterone are clomiphene (off-label, fertility-preserving), enclomiphene (also off-label), or testosterone replacement therapy (which suppresses fertility, sometimes permanently). A GLP-1 is now a credible fourth option, especially if obesity is also driving cardiovascular risk that’s worth treating on its own.</p><p>Important caveat for fertility specifically: you don’t want to be on a GLP-1 the month you’re trying to conceive. Both semaglutide and tirzepatide carry warnings about discontinuation before pregnancy because we don’t have safety data in early pregnancy, and the package inserts recommend stopping at least two months before trying to conceive on the male side and longer on the female side. The fertility benefits are about getting your hormones and sperm parameters into a better state. The conception itself should happen during a planned washout period.</p><p>If you’re trying to figure out whether a GLP-1 is appropriate for you and where to start, I wrote a <a href="https://glp1clinics.org/blog/glp1-male-fertility-sperm-count-recovery-2026-04-22">deeper breakdown of the male fertility evidence</a> that goes into the specific lab markers worth tracking. Worth a read if this matches your situation.</p><h3>The Industry Hasn’t Caught Up Yet</h3><p>Here’s something that surprised me. Almost none of the telehealth GLP-1 platforms market themselves around male fertility benefits. They market around weight loss. They market a little around diabetes. Some are starting to market around cardiovascular risk reduction. Fertility doesn’t show up.</p><p>Part of that is regulatory. None of these drugs are FDA-approved for male fertility, so claiming a fertility benefit in marketing copy is a fast track to a warning letter. Part of it is just that the patient population doesn’t ask for it yet because the story isn’t widely known.</p><p>For the men who’d benefit, the practical reality is that you’ll mostly need to bring this up with your own physician. Find a doctor (urologist, endocrinologist, or a GLP-1 specialist) who’s read the recent literature and is willing to consider semaglutide or tirzepatide as part of a male hypogonadism workup. If you want to compare options, the directory side of <a href="https://glp1clinics.org/telehealth-providers">GLP-1 telehealth providers we cover</a> has the ones that prescribe for broader metabolic health, not just weight loss.</p><h3>Where I Land</h3><p>The “Ozempic babies” headline is a goofy way to talk about what’s actually happening. The real story is that we may have stumbled into a genuinely useful intervention for a category of male infertility that historically was treated either with pretty crude hormone manipulation or with the standard “lose weight and come back in six months” advice that almost nobody actually executes on.</p><p>The data is still early. The effect sizes are real but modest. The mechanism makes biological sense. And the side effect profile of GLP-1s is reasonably well characterized at this point.</p><p>For an obese man with low testosterone and subfertility, this is a credible option that deserves a serious conversation with the right specialist. For a lean man with normal testosterone who saw a tweet about Ozempic boosting sperm counts and is wondering if he should microdose tirzepatide for fertility “optimization”: probably not. The data doesn’t support that population, and the risks aren’t zero.</p><p>The story will be a lot clearer two years from now when the first generation of properly designed fertility outcome trials reports out. Until then, this is one of those cases where the science is genuinely interesting and the headlines have buried the lede.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=42c975bc202f" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[GLP-1s Are Eating Your Muscle. The Drugs Designed to Stop That Are Almost Here.]]></title>
            <link>https://medium.com/@robertchristos/glp-1s-are-eating-your-muscle-the-drugs-designed-to-stop-that-are-almost-here-350add01a535?source=rss-a810eec1c502------2</link>
            <guid isPermaLink="false">https://medium.com/p/350add01a535</guid>
            <category><![CDATA[health]]></category>
            <category><![CDATA[fitness]]></category>
            <category><![CDATA[glp-1]]></category>
            <category><![CDATA[medicine]]></category>
            <dc:creator><![CDATA[Robert Christos Nelson]]></dc:creator>
            <pubDate>Wed, 29 Apr 2026 17:39:53 GMT</pubDate>
            <atom:updated>2026-04-29T17:39:53.295Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*PpZHCrLcMSh2XqDCfW2B7A.png" /></figure><p>A new class of antibodies is showing up in late-stage trials that, when added to semaglutide, preserves lean mass and accelerates fat loss at the same time. Here’s what’s actually in the pipeline and when you’ll see it.</p><p>I’ve been writing about GLP-1s for a while now, and the muscle-loss problem is the most consistent reader question I get. Some version of: “I’m down 40 pounds on Zepbound, but my arms look smaller than my husband’s, and my doctor said my grip strength is in the bottom 10%. Is this normal?”</p><p>The honest answer is yes. It’s also not great. And the fix that’s coming is a class of drugs almost nobody talks about outside of clinical trial readouts and pharma earnings calls.</p><p>I went down this rabbit hole when I saw the Phase 2 readout from the COURAGE trial drop. Once I understood what Regeneron, Lilly, and Roche were actually building, the future of obesity medicine looked very different than the present.</p><p>Let me walk through what’s coming, because if you’re on a GLP-1 right now, this matters for your treatment plan in the next two to three years.</p><h3>The Muscle Problem Nobody Wants to Talk About</h3><p>Every weight loss intervention causes some lean mass loss alongside fat loss. That’s true for diet alone, surgery, and every weight loss drug we’ve ever had. The question has always been the ratio.</p><p>For diet alone, the typical split is roughly 75% fat to 25% lean. That’s already not great, but at least most of what you’re losing is what you wanted to lose.</p><p>For semaglutide and tirzepatide, the data is messier than people realize. The interim Phase 2 COURAGE trial data, which I’ll get to in detail in a second, showed that semaglutide alone drove a 15.7% reduction in fat mass and a 6.5% reduction in lean mass in adults with obesity over 26 weeks. So roughly a 70/30 split, fat to lean. That’s roughly in line with diet alone, maybe slightly worse.</p><p>For a lot of people that’s fine. If you’re carrying 50 pounds of excess body weight and you lose 35 pounds of fat plus 15 pounds of lean tissue, you’re still vastly better off metabolically. The lean mass loss isn’t all “muscle” in the gym sense, either. A significant chunk is water, glycogen, and connective tissue that comes off with the fat.</p><p>But there’s a population this hits harder. Older adults, especially women in or past menopause, who are already losing about 1% of muscle mass per year just from aging. Strip an additional 6 to 10% off in six months on top of that, and you’ve put someone who was functionally independent at real risk of frailty, falls, and the cascade of bad outcomes that follow. Some endocrinologists are starting to think the standard GLP-1 dose schedule is genuinely inappropriate for patients over 70 unless there’s a serious effort on resistance training and protein.</p><p>The pharma industry noticed.</p><h3>The Myostatin Story</h3><p>Myostatin is a protein your body produces specifically to limit how much muscle you can build. It’s a brake. Block the brake, and muscle growth accelerates. This has been understood for decades. There are dogs and cattle bred to have natural myostatin loss-of-function mutations, and they look like cartoon characters of their species. Solid muscle, low body fat, the whole deal.</p><p>Drug developers have been trying to make myostatin-blocking antibodies for human use since the early 2000s, mostly for muscular dystrophies and sarcopenia. The early efforts mostly failed in primary endpoints. Bimagrumab, taldefgrobep, and several others showed they could increase lean mass in trials but couldn’t translate that into the functional improvements regulators wanted to see for muscle disease indications.</p><p>Then GLP-1s exploded as a category, and somebody at Regeneron looked at the pipeline of failed myostatin antibodies, looked at the muscle loss problem with semaglutide, and said: what if we combined them.</p><p>That’s what’s now being tested in <a href="https://investor.regeneron.com/news-releases/news-release-details/results-phase-2-courage-trial-demonstrating-potential-improve">the Phase 2 COURAGE trial</a>. Regeneron’s pairing semaglutide with trevogrumab (an anti-myostatin antibody) and garetosmab (an anti-Activin A antibody, which works on a related muscle-suppressing pathway). The interim results, presented at the European Association for the Study of Diabetes meeting, are striking.</p><h3>The COURAGE Numbers Are Hard to Ignore</h3><p>Here’s the breakdown over 26 weeks in adults with BMI ≥30:</p><ul><li><strong>Semaglutide alone:</strong> -15.7% fat mass, -6.5% lean mass.</li><li><strong>Semaglutide + trevogrumab:</strong> -19.1% fat mass, -3.3 to -3.8% lean mass.</li><li><strong>Semaglutide + trevogrumab + garetosmab (the triple combo):</strong> -27.1% fat mass, -2.0% lean mass.</li></ul><p>Read that last line again. Twenty-seven percent fat reduction. Two percent lean reduction. That’s a body composition change that historically required the kind of disciplined contest prep regimen used by professional bodybuilders, not a once-weekly injection.</p><p>The mechanism is actually elegant. The GLP-1 drives appetite suppression and a caloric deficit. The myostatin blocker partially uncouples lean tissue loss from that deficit, allowing fat to come off without your body cannibalizing muscle to do it. The Activin A blocker amplifies the same pathway from a different angle. The combination effect is more than additive.</p><p>Worth noting: this is interim Phase 2 data. The final readout is expected in 2026. Phase 2 trials are small and short. We don’t know yet whether the lean mass preservation translates into functional outcomes that matter (grip strength, walking speed, ability to get up from a chair) or whether it shows up as cosmetic improvement only. Phase 3 trials will need to demonstrate that.</p><p>We also don’t know the long-term side effect profile of myostatin and Activin A blockade. Earlier myostatin-blocker trials in DMD patients had some safety signals around tendon and ligament integrity, since myostatin also regulates connective tissue. Whether those concerns translate to a healthy obese population at the doses being tested in COURAGE is an open question.</p><h3>The Other Players</h3><p>Regeneron isn’t the only one chasing this. <a href="https://www.pharmacytimes.com/view/bimagrumab-semaglutide-combination-achieves-significant-weight-loss-while-preserving-muscle-mass">A bimagrumab-plus-semaglutide combination</a>, also called bamagrumab in some publications, has shown similar effects. Bimagrumab targets the activin Type II receptor, which is upstream of both myostatin and Activin A. Phase 2 data in obese adults with type 2 diabetes showed meaningful preservation of lean mass alongside continued fat loss.</p><p>Lilly is in the space too, though they’ve been quieter about specifics. Their angle is likely to be a combination product that pairs their existing tirzepatide franchise with a muscle-preservation agent rather than a separate add-on injection. That’s a hard pharma engineering problem but a much better commercial story.</p><p>Taldefgrobep, an earlier myostatin antibody from BMS that didn’t work for Duchenne muscular dystrophy, is now being studied in obesity. <a href="https://link.springer.com/article/10.1007/s11154-025-09967-4">A 2025 review in Reviews in Endocrine and Metabolic Disorders</a> covered the broader landscape and noted that essentially every major obesity-drug developer now has a muscle-preservation program of some kind in the pipeline.</p><p>The competitive dynamic is interesting. Whoever ships the first FDA-approved combo therapy that preserves lean mass during GLP-1 weight loss is going to lap the field on outcomes data. The obesity drug category is moving from “how much weight do you lose” to “what’s the quality of the weight you lose,” and that’s a structurally different conversation.</p><h3>What This Means If You’re On a GLP-1 Today</h3><p>The first muscle-preservation combo isn’t going to be FDA-approved before 2027 at the earliest, and probably 2028 if I had to guess. So the practical question is: what do you do in the meantime?</p><p>The two interventions that have actual evidence behind them right now are protein and resistance training. Boring, well-established, and effective.</p><p>For protein: most adults on a GLP-1 should be aiming for at least 1.2 to 1.6 grams per kilogram of body weight per day, which is meaningfully higher than the standard 0.8 g/kg recommendation. For someone who weighs 200 pounds (90 kg), that’s roughly 110 to 145 grams of protein per day. That’s a lot more than most people on a GLP-1 actually eat, because the appetite suppression makes hitting any calorie target hard, let alone a protein target. This is the single most common nutritional mistake I see.</p><p>For resistance training: two to three sessions a week of compound movements (squats, deadlifts, presses, rows) is enough to substantially reduce lean mass loss in essentially every weight loss intervention that’s been studied with this question in mind. You don’t need to be in the gym five days a week. You do need to lift heavy things in some form on a regular schedule.</p><p>I wrote a more detailed piece on the <a href="https://glp1clinics.org/blog/myostatin-inhibitors-muscle-preservation-glp1-2026-04-24">myostatin inhibitor pipeline and what to do in the meantime</a> if you want a deeper look at the specific drugs and timelines.</p><h3>The Bigger Picture</h3><p>What’s happening in this space is part of a broader pattern. The first generation of obesity drugs (Wegovy, Zepbound, soon Foundayo) cracked the “can we get people to lose substantial weight” problem. The second generation, which is starting to show up in trials now, is going to be about the quality of the weight loss. Muscle preservation is one piece. Improved metabolic markers, cardiovascular outcomes, and cognitive effects are the others.</p><p>Retatrutide, Lilly’s triple-agonist GLP-1 / GIP / glucagon drug, is part of this same generational shift. The Phase 2 data showed 24% body weight loss at 48 weeks, but the more interesting numbers are around how that loss is distributed and what happens to liver fat, blood pressure, and lipid panels at the same time.</p><p>If you’re starting a GLP-1 today and you’re under 50 with no immediate muscle-loss concerns, you’re fine. The standard drugs work, the side effect profile is well characterized, and you can manage the lean mass piece with protein and lifting. If you’re in your 60s or 70s and starting one, the calculus is different. The standard dose schedule was developed in mostly middle-aged populations, and the muscle-loss tradeoff is steeper for older patients. Pushing your provider for a more conservative titration and a more aggressive resistance training plan isn’t wrong.</p><p>And if you’re considering whether to start now versus wait for the next generation: don’t wait. You’ll be on a GLP-1 for years. The first-gen drugs are good enough that the cardiometabolic benefits compound from day one, and you can switch to a combination product later when one ships. Waiting two years for a marginally better drug while keeping 40 extra pounds of metabolic risk is the wrong trade.</p><p>The obesity treatment landscape five years from now is going to look meaningfully different than today. That’s a good thing for patients. It’s also going to be a useful corrective to the public conversation around these drugs, which is still mostly stuck on either “miracle” or “Ozempic face” without a lot in between.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=350add01a535" width="1" height="1" alt="">]]></content:encoded>
        </item>
    </channel>
</rss>